



24th European Paediatric Rheumatology Congress



Athens

Greece

14-17 September 2017

Under the Auspices of H.E. the President of the Hellenic Republic Mr. Prokopios Pavlopoulos

Final Programme



PRs is a European scientific society for healthcare professionals in the field of paediatric rheumatology.

PRES



25th EUROPEAN
PAEDIATRIC
RHEUMATOLOGY
CONGRESS

LISBON • PORTUGAL – 5-8 SEPTEMBER 2018

SAVE THE DATE



REGISTER YOUR INTEREST

For information email pres@mci-group.com website www.pres.eu

CONTENTS

ACKNOWLEDGMENTS	4
COMMITTEE PRESENTATION	4
WELCOME MESSAGE	5
GENERAL INFORMATION	6
NETWORKING OPPORTUNITIES	8
SCIENTIFIC INFORMATION	10
WORKING PARTIES MEETING & PReS EXTRA MEETINGS	11
SCIENTIFIC PROGRAMME	12
THURSDAY 14 SEPTEMBER	14
FRIDAY 15 SEPTEMBER	14
SATURDAY 16 SEPTEMBER	28
SUNDAY 17 SEPTEMBER	42
SATELLITE SYMPOSIA PROGRAMMES	48
SPONSORS AND EXHIBITORS PROFILES	48
MAPS	52

ACKNOWLEDGMENTS

PReS would like to formally thank the following persons who have reviewed the abstracts submitted for the congress:

Tadej Avcin	Michael Hofer	Johannes Roth
Michael Beresford	Gerd Horneff	Nicolino Ruperto
Rolando Cimaz	Isabelle Koné-Paut	Elena Tsitsami
Alessandro Consolaro	Clara Malattia	Yosef Uziel
Fabrizio De Benedetti	Alberto Martini	Jelena Vojinovic
Ivan Foeldvari	Susan Mary Nielsen	Lucy Wedderburn
Helen Foster	Clarissa Pilkington	Nico Wulffraat
Joost Frenkel	Pierre Quartier	Francesco Zulian
Marco Gattorno	Angelo Ravelli	

COMMITTEE PRESENTATION

SCIENTIFIC PROGRAMME COMMITTEE

Tadej Avcin (*Slovenia*) – **Chair**
 Alexandre Belot (*France*)
 Michael Beresford (*United Kingdom*)
 Johannes Bijlsma (*The Netherlands*)
 Mette Nørgaard (*Denmark*)
 Johannes Roth (*Germany*)
 Joost Swart (*The Netherlands*)
 Elena Tsitsami (*Greece*)
 Janjaap van der Net (*The Netherlands*)
 Lucy Wedderburn (*United Kingdom*)
 Francesco Zulian (*Italy*)

LOCAL ORGANISING COMMITTEE

Elena Tsitsami – **President**
 Maria Tsinti
 Vasiliki Dermentzoglou
 Evangelia Charmandari
 Christina Kanaka-Gantenbein
 Ioannis Anastasopoulos
 Kleio Mavragani
 Olga Vougiouka

PReS COUNCIL MEMBERS

Berent Prakken (*The Netherlands*) – **President**
 Michael Hofer (*Switzerland*) – **Secretary**
 Angelo Ravelli (*Italy*) – **Treasurer**
 Tadej Avcin (*Slovenia*) – **Chair, Training and Education committee**
 Rolando Cimaz (*Italy*) – **Chair, Research Committee**
 Carine Wouters (*Belgium*) – **Chair, Clinical Affairs Committee**
 Jan-Jaap van der Net (*The Netherlands*) – **Chair, Allied Health Professionals**
 Eve Smith (*United Kingdom*) – **Trainee Representative**
 Nicola Ruperto (*Italy*) – **Chair of PRINTO**
 Yona Egert (*Israel*) – **ENCA representative**

PReS HONORARY MEMBERS

Patricia Woo (*United Kingdom*)
 Anne-Marie Prieur (*France*)
 Wietse Kuis (*The Netherlands*)

WELCOME MESSAGE

WELCOME MESSAGE FROM BERENT PRAKKEN:

Dear Friends,

It is with the utmost pleasure that I welcome you to the 2017 Annual Congress of PReS in Athens.

We are extremely happy that Athens, the birthplace of so much culture and science, hosts PReS for our 24th congress. In these 24 years much progress has been made in paediatric rheumatology. We moved from gold injections and steroids to biologics and biomarkers. But many challenges remain; not only for clinicians that take care of patients and for scientists that try to unravel these complex diseases but foremost, for patients that have to cope with the burden of disease every day. We still have much work to do!

I am convinced that the inspirational environment of Greek culture will once again stimulate vibrant and lively discussions between professionals, scientists and patients that may lead to new collaborations, ideas and initiatives that will shape the field of paediatric rheumatology.

Wishing you a successful congress!



Berent Prakken
President of PReS

WELCOME MESSAGE FROM ELENA TSITSAMI:


Dear Colleagues,

On behalf of the Paediatric Rheumatology European Society, as well as the Organising Committee and the Scientific Committee, I would like to welcome you to the 24th European Paediatric Rheumatology Congress (PReS 2017) in Athens.

Continuing the successful trend of past Congresses, the PReS 2017 Congress features presentations of some of the most recent research and trials, and robust debates on the clinical challenges paediatric rheumatologists face today, whilst we are expecting practice-changing abstracts and timely data to be presented. Moreover, the Congress provides unique opportunities to network with leadership in Paediatric Rheumatology and enjoy enlightened and innovative learning experiences that highlight the most up-to-date, evidence-based developments in the field!

Athens is a metropolitan city that combines both the old and the modern, the spirit of future with the treasures of the past. Its many historical and physical attractions and close proximity to breath-taking surroundings, the appropriate infrastructure and world-class facilities will contribute to a successful outcome. The local organisation team has worked hard to offer you an unforgettable experience.

Sincerely yours,



Elena Tsitsami
President of the Local Organising Committee

GENERAL INFORMATION

CONGRESS VENUE – DATES & LOCATION

PRoS 2017 congress is held at:
 Megaron Athens International Conference Centre - MAICC
 Vas.Sofias Ave. & Kokkali St.
 Athens 11521
 Greece

THE CONGRESS OPENS ON
Thursday 14 September 2017

AND CLOSSES ON
Sunday 17 September 2017

CONTACTS

ORGANISING SECRETARIAT

PRoS 2017
 c/o MCI Suisse SA
 9, Rue du Pré-Bouvier
 1242 Satigny, Geneva
 Switzerland
 Email: pres@mci-group.com



EXHIBITION & SPONSORSHIP

Tel: +41 22 33 99 650
 Email: christopher.day@mci-group.com

SPEAKERS & ABSTRACT HANDLING

Tel: +41 22 33 99 667
 Email: gaelle.vacca@mci-group.com
 Email: pres.abs@mci-group.com

REGISTRATION & ACCOMMODATION

Tel: +41 22 33 99 720
 Fax: +41 22 33 99 631
 Email: pres.regshot@mci-group.com

LOCAL ORGANISING AGENCY

PCO Convin
 29 K. Varnali Str., Chalandri
 Athens, Greece, GR15233
 Tel: +30 210 6833600
 Fax: +30 210 6847700
 Email: info@pco-convin.gr

REGISTRATION AND SPEAKERS DESK

Thursday 14 September	10:00-20:00
Friday 15 September	07:30-19:00
Saturday 16 September	07:30-18:30
Sunday 17 September	08:00-14:30

ATTENDANCE

Meeting rooms vary in size. Should the scientific session of your choice be fully attended, we invite you to attend a different scientific session. Neither PReS nor MCI can be held responsible should a delegate be unable to attend a scientific session due to the capacity of the allocated meeting room.

CASH MACHINE

A cash dispenser is located on the ground floor at Entrance A of the congress center.

CELLULAR PHONES

As a courtesy to all congress attendees and speakers, cellular phones, and other electronic devices must be operated in silent/vibrate mode during sessions. Devices that ring, beep, etc. are strictly prohibited. No cellular phone conversations are permitted during sessions/meetings.

CERTIFICATE OF ATTENDANCE

A personalised certificate of attendance will be sent by email to all attendees, in digital format, after the congress.

CONGRESS DOCUMENTS & BADGES

Congress documents and badges must be collected at the registration desk at the congress venue, level -1. Name badges must be worn at all time during the congress.

CYBER CAFÉ

With the kind support of Alexion

A Cyber café located in the exhibition area is available to all registered delegates to browse the internet.

ELECTRICITY

Electrical sockets comply with European regulations. In Greece the power sockets are of type C and F. The standard voltage is 230 V and the standard frequency is 50 Hz.

FOOD & BEVERAGE

Coffee and tea during official breaks are included in the registration fee and will be served in designated areas. A cash bar (MShop) will be open during the congress at level -1 should you wish to purchase light food and beverage besides coffee breaks.

INSURANCE AND LIABILITY

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. PReS and MCI as organisers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants.

LANGUAGE

The official congress language is English. All sessions will be given in English. No simultaneous translation is provided.

MOBILE APPLICATION

With the kind support of Abbvie

Get all the information you need on your fingertips with the PReS 2017 mobile app.

The app is available for free on iOS and Android.

SERVICES FOR THE DISABLED

There is a lift access to all floors in the venue.

SESSIONS RECORDING

In the permanent ambition to support the Pediatric Rheumatology community with the best available information, PReS is collecting the contributions from all presenters of the PReS 2017 Congress in digitally recorded format.

The purpose of the recording is to make these State-of-the-Art presentations available to a wider audience and with this, the latest progress in the field will also be available to those not able to follow the proceedings during the congress.

- The access to these presentations is included in the Full Congress Registration fee for an additional cost of EUR 50
- The presentations will be recorded as a series of slides, accompanied by the speaker spoken comments and explanations during the session
- The presentations will be accessible approximately 2 weeks after the congress
- The presentations will be accessible during 12 months after launch of the online platform

SMOKING POLICY

Smoking in the congress centre is NOT allowed.

TELEPHONE

To call a Greek telephone number from outside Greece, either from a landline or a mobile phone, you will need to add the international dialing code for Greece, 0030 (+30), followed by the phone number you require.

WIFI

Free WiFi will be available at the venue for all PReS 2017 participants. Login information is provided on site when you collect your registration materials.

NETWORKING OPPORTUNITIES

Opening Ceremony & Networking Reception

**THURSDAY 14 SEPTEMBER 2017
FROM 18:00**

Come and share a great moment of conviviality with your colleagues from all over the world.

All registered participants are welcome.

PRoS 2017 Networking Dinner – Ticketed Event

**SATURDAY 16 SEPTEMBER 2017
FROM 20:30 AT ZAPPEION PERISTILIO**

Join your colleagues from all over the world to continue your exchanges with colleagues and fellow congress attendees in a relaxed atmosphere.

The Zappeion Exhibition Hall was the first building in the world to be constructed in order to serve Olympic needs.

Its architecture is in the neoclassical order, with a Corinthian portico, and an organization of spaces that is fully in harmony with the purpose for which it was built. This building, the three-arched stone bridge over the Ilissus River that had been repaired, also at the expense of Evangelis Zappas, and the surrounding gardens give us a charming picture of Athens in the early 20th century.

Attendance upon registration – please check availability of tickets at the registration desk

FEE: 95 EUR

DRESS CODE: Smart casual



The Journal of Rheumatology

First Release Articles
Current Issue
Archives
Authors/Reviewers

Visit jrheum.org to view our new website



What you get

- ↖ **Current**
- ↖ **Clinical**
- ↖ **Definitive**

Where you get it **THE JOURNAL**

To subscribe: visit jrheum.org online or send in your completed coupon below

Rates for 2017 calendar year USA/INTERNATIONAL

	Print + Online	Online Only
INDIVIDUALS:	\$350 US	\$285 US
INSTITUTIONAL:		
- Multisite [#]	On request	On request
- Multiuser (IP ranges)	\$1025 US	\$975 US
- Basic-Plus (IP ranges)	\$750 US	\$700 US
- Basic (up to 4 users)	\$550 US	\$500 US
TRAINEES⁺	\$215 US	\$150 US ⁺
AIRMAIL (ADD)	\$120 US	

For terms of access visit jrheum.org
[#]Supervisor certification required below.

NAME OF SUPERVISOR: _____

SUPERVISOR SIGNATURE: _____

SUPERVISOR TELEPHONE: _____

Please enter my 2017 subscription to **The Journal of Rheumatology**

Name (please print) _____

Address _____

City _____ State/Province _____

Country _____ Zip/Postal Code _____

Contact E-mail _____

Amount Enclosed \$ _____ Bill Me _____

Telephone Number _____ Fax Number _____

VISA/MasterCard Number _____ Expiration Date _____

Signature _____ CVV _____

Mail completed form to: **The Journal of Rheumatology**
 365 Bloor Street East, Suite 901 | Phone: (416) 967-5155
 Toronto, Ontario Canada M4W 3L4 | Fax: (416) 967-7556
 E-mail: subscriptions@jrheum.com

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2017 will be charged an additional \$10 per back issue. Back issues: 2 years including current year are available if in stock. Single copies are available at \$30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January Issue. **PRIVACY POLICY:** For details of our privacy policy, visit our website at www.jrheum.org.

SCIENTIFIC INFORMATION

SPEAKERS' PREVIEW ROOM

A Speakers' Preview Room is available at the room MC 3.3 (level -1) and is open at the following hours:

Thursday 14 September	13:00-19:00
Friday 15 September	07:30-19:00
Saturday 16 September	07:30-19:00
Sunday 17 September	07:30-11:30

The speaker centre is equipped with computers. All speakers are required to check in their presentation at least 2 hours before their session, or on the day before for the early morning sessions.

POSTERS

The scientific posters are located in Skalkotas Foyer (level -1) and Banquet Foyer (level -2).

Official Poster Viewing will take place at the following hours:

Friday 15 September	14:00-15:00
Saturday 16 September	14:00-15:00

Guided Poster Tours on selected topics are taking place at the following hours:

Friday 15 September	14:00-15:00
Saturday 16 September	14:00-15:00

Presenting authors are requested to stay in front of their poster and to be available for discussion at the above times.

SATELLITE LUNCHTIME SYMPOSIA

A number of satellite lunchtime symposia are organized during PReS 2017:

Abbvie	Friday 15 September	13:00-14:00
Pfizer	Friday 15 September	13:00-14:00
BioMarin & Sanofi Genzyme	Friday 15 September	13:00-14:00
Novartis	Saturday 16 September	13:00-14:00
Enzyvant	Saturday 16 September	13:00-14:00

EXHIBITION

During the congress, PReS wishes to present an attractive exhibition to the congress participants.

Coffee breaks are served in the exhibition area, Skalkotas Foyer (level -1)

The exhibition will be open at the following times:

Thursday 14 September	19:30-21:00
Friday 15 September	09:30-17:30
Saturday 16 September	09:30-17:30
Sunday 17 September	09:30-11:30

WORKING PARTIES MEETINGS & PRES EXTRA MEETINGS

THURSDAY 14 SEPTEMBER

	MC 2 LEVEL -1	MC 3.5 LEVEL -1	MC 3.2 LEVEL -1	MC 3.4 LEVEL -1	Room 1 LEVEL 1 (ENTRANCE A)	Room 2 LEVEL 1 (ENTRANCE A)	Room 3 LEVEL 1 (ENTRANCE A)	Room 4 LEVEL 1 (ENTRANCE A)
• 13:30								
• 14:00	HPPR ANNUAL MEETING 14:00 - 17:00	PRINTO COUNCIL MEETING 14:00 - 16:00	JDM WP MEETING 14:00 - 15:30	VASCULITIS WP MEETING 14:00 - 15:30	IMAGING WP MEETING 14:00 - 15:30	UVEITIS WP MEETING 14:00 - 15:30		UCAN MEETING 14:00 - 15:30
• 14:30								
• 15:00								
• 15:30								
• 16:00			SLE WP MEETING 16:00 - 17:30	TRAINEES MEETING 16:00 - 17:30	AUTO-INFLAMMATION WP MEETING 16:00 - 17:00	SCLERODERMA WP MEETING 16:00 - 17:30	MAS WP MEETING 16:00 - 17:30	UCAN MEETING 16:00 - 17:30
• 16:30								
• 17:00								
• 17:30								
• 18:00								

FRIDAY 15 SEPTEMBER

	MC 3 LEVEL -1	MC 2 LEVEL -1
• 07:30		
• 08:00		BIOMED CENTRAL WORKSHOP 07:30 - 08:30
• 08:30		
• 14:00		
• 14:30	PRINTO / ERN MEETING 14:00 - 15:00	
• 15:00		

SATURDAY 16 SEPTEMBER

	MC 3.2 LEVEL -1
• 07:30	
• 08:00	EDUCATION & TRAINING COMMITTEE MEETING 07:30 - 08:30
• 08:30	
• 14:00	
• 14:30	PRES ANNUAL GENERAL ASSEMBLY 14:00 - 15:00
• 15:00	

PROGRAMME AT-A-GLANCE

THURSDAY 14 SEPTEMBER 2017

14:00 - 18:00	PReS working party meetings meetings	14:00 - 17:00	Annual HPPR Meeting
---------------	--------------------------------------	---------------	---------------------

BANQUET HALL

18:00 - 20:00	Opening plenary and Welcome addresses
20:00 - 21:30	Networking Reception

FRIDAY 15 SEPTEMBER 2017

	BANQUET HALL	SKALKOTAS HALL	MC3 ROOM	MC2 ROOM
	PReS Congress	PReS Congress	PReS Congress	ENCA Day 1
07:30 - 08:30				BioMed Central Workshop
08:30 - 09:00	A year in review: Basic and translational science			
09:00-10:30	Clinical aspects and treatment of SLE	Big data analytics		ENCA - Other inflammatory diseases, latest research and PReS
10:30-11:00	Coffee Break			
11:00-12:30	Remission and outcome of systemic lupus erythematosus (SLE)	Immunometabolomics		ENCA - Focus group
12:30-15:00	Lunch Break			
13:00-14:00	Satellite Symposium - ABBVIE	Satellite Symposium - PFIZER	Satellite Symposium - BIOMARIN & SANOFI GENZYME	14:00-14:30 ENCA - New developments and new strategies : optimising treatment in JIA
14:00-15:00	Lunch Break		PRINTO / ERN Meeting	
15:00-17:00	Autoinflammatory diseases in practice	PReS/ENCA joint session: Parent and child perspectives on physician communication in Pediatric Rheumatology		
17:00-17:30	Coffee Break			
17:30-18:30	State-of-the-art presentations	Genetic aspects of pediatric rheumatic diseases		
18:30-19:00				











Clinical Science and Practice



Basic and Translational Science

PROGRAMME AT-A-GLANCE

SATURDAY 16 SEPTEMBER 2017				
	BANQUET HALL	SKALKOTAS HALL	MC3.2 ROOM	MC2 ROOM
	PRoS Congress	PRoS Congress	HPPR Day 1	ENCA Day 2
07:30 - 08:30		PRoS Education & Training Committee Meeting		
08:30 - 09:00	A year in review: Clinical and health sciences			
09:00-10:30	Remission in chronic arthritis 	New insights into the pathogenesis of SLE 	HPPR 1: Workshop on Clinical rehabilitation skills in JIA	ENCA - Adolescent issues
10:30-11:00	Coffee Break			
11:00-12:30	Scleroderma and related disorders 	Pathogenesis of antiphospholipid syndrome in pediatric populations 	HPPR 2: Workshop on Medication and health counseling	ENCA - Session/teenage, drugs, alcohol, sex
12:30-15:00	Lunch Break			
13:00-14:00	Satellite Symposium - NOVARTIS	Satellite Symposium - ENZYVANT		
14:00-15:00	Lunch Break & Poster Viewing		PRoS AGM	ENCA: Self-management and pain management
15:00-17:00	Pathogenesis of JIA 	PRoS/HPPR joint session: Exercise therapy, physical activity and sport in JIA		15:00-16:00 - ENCA
17:00-17:30	Coffee Break			
17:30-19:00	Oral presentations		HPPR 3: Workshop: Teaching Clinical Skills	

SUNDAY 17 SEPTEMBER 2017		
	BANQUET HALL	SKALKOTAS HALL
	PRoS Congress	PRoS Congress
08:30 - 10:00	Oral presentations	
10:30-10:30	Coffee Break	
10:30-11:30	Epidemiology and challenges in management of childhood-onset SLE around the World 10:30 - 12:15 	Pharmacotherapy of juvenile idiopathic arthritis (JIA) 10:30 - 11:30 
11:30 - 12:15		
12:10-12:30	Coffee Break	
12:30 - 14:00	Thieves market 	
14:00-14:30	Closing	

THURSDAY 14 SEPTEMBER

SCIENTIFIC SESSIONS

18:00 - 20:00	Opening plenary and welcome addresses	Banquet Hall
	<i>Chairs: Berent Prakken (The Netherlands), Elena Tsitsami (Greece)</i>	
18:00	Welcome address: President of PReS	
18:15	Welcome address: President of Local Organizing Committee	
18:25	HPPR address	
18:32	ENCA address	
18:40	YIM best abstract presentation - basic science	
18:50	YIM best abstract presentation - clinical science	

BARBARA ANSELL KEYNOTE LECTURE

19:00	Molecular and cellular mechanisms driving chronic inflammation and autoimmunity
	<i>George Kollias (Greece)</i>
19:30	Performance
20:00	Networking Reception

FRIDAY 15 SEPTEMBER

SPECIAL SESSION

07:30 - 08:30	How to review journal manuscripts for trainees and young faculty?	Room MC2
---------------	--	-----------------

PReS SESSIONS

08:30 - 09:00	A year in review: Basic and translational science	Banquet Hall
	<i>Chairs: Michael Beresford (United Kingdom), Seza Ozen (Turkey)</i>	
	<i>Speaker: Fabrizio de Benedetti (Italy)</i>	
09:00 - 10:30	● Clinical aspects and treatment of systemic lupus erythematosus (SLE)	Banquet Hall
	<i>Chairs: Michael Beresford (United Kingdom), Seza Ozen (Turkey) and Eve Smith (United Kingdom)</i>	
09:00	Urinary biomarkers in childhood lupus nephritis	
	<i>Michael Beresford (United Kingdom)</i>	
09:25	Assessment and management of neuropsychiatric symptoms in childhood-onset systemic lupus erythematosus (SLE)	
	<i>Simone Appenzeller (Brazil)</i>	
09:50	New therapeutic targets in systemic lupus erythematosus (SLE)	
	<i>David Isenberg (United Kingdom)</i>	
10:15	O1 - JSLE and the NLRP3 inflammasome – a novel therapeutic target	
	<i>Jo Gamble (United Kingdom)</i>	
09:00 - 10:30	■ Big data analytics	Skalkotas Hall
	<i>Chairs: Dimitris Vassilopoulos (Greece), Joost Swart (The Netherlands)</i>	
09:00	How to deal with big data in research and clinics	
	<i>Vicki Seyfert-Margolis (USA)</i>	
09:25	Understanding Childhood Arthritis Network (UCAN) for improving research efficiency in pediatric rheumatology	
	<i>Rae Yeung (Canada)</i>	



- 09:50 Big data and precision medicine in pediatric rheumatology
Joo Guan Yeo (Singapore)
- 10:15 **O4** - Using blood transcriptomic data for disease etiology discovery in pediatric ANCA-associated vasculitis
Erin Gill (Canada)

ENCA SESSION

09:00 - 10:30 **ENCA Programme** MC2 Room
Please refer to page 44 for further details

10:30-11:00 **Coffee break**

PReS SESSIONS

11:00 - 12:30 **● Remission and outcome of systemic lupus erythematosus (SLE)** Banquet Hall
Chairs: Clarissa Pilkington (United Kingdom), Sylvia Kamphuis (The Netherlands) and Maria Tisinti (Greece)

- 11:00 Response measures in systemic lupus erythematosus (SLE)
Hermine Brunner (USA)
- 11:20 Long-term outcome of childhood-onset systemic lupus erythematosus (SLE)
Earl Silverman (Canada)
- 11:40 Vaccination in patients with systemic lupus erythematosus (SLE) and other chronic autoimmune diseases
Nico Wulffraat (The Netherlands)
- 12:00 **O5** - Impact of fatigue, depressive symptoms and skin symptoms in adults with childhood-onset systemic lupus erythematosus (SLE) and the relation with HRQOL – the chill-NL study
Ayse Kaynak (The Netherlands)
- 12:10 **O6** - Clinical predictors of developing lupus nephritis in children
Eve Smith (United Kingdom)
- 12:20 **O6b** - Decreased antibodies against rubella in previously vaccinated treatment naïve-jSLE patients: a prospective case control study
Despoina Maritsi (Greece)

11:00 - 12:30 **■ Immunometabolomics** Skalkotas Hall
Chairs: Fabrizio de Benedetti (Italy), Jordi Anton (Spain)

- 11:00 Pynin inflammasome activation in familial Mediterranean fever (FMF)
Jae Jin Chae (USA)
- 11:30 Molecular mechanisms of inflammation in mevalonate kinase (MVK) deficiency
Donghai Wang (USA)
- 12:00 **O7** - NRF2 enhances metabolic turnover in myeloid cells resulting in expansion of CD11B+GR-1+ MDSCs
Klaus Tenbrock (Germany)
- 12:15 **O8** - Novel serum broad-based proteomic discovery analysis identifies proteins and pathways dysregulated in juvenile dermatomyositis (JDM)
Hanna Kim (USA)

ENCA SESSION

11:00 - 12:30 **ENCA Programme** MC2 Room
Please refer to page 44 for further details

12:30-15:00 **Lunch break**



SPONSORED SYMPOSIA

13:00 - 14:00	Satellite Symposium ABBIVE See detailed programme page 46	Banquet Hall
13:00 - 14:00	Satellite Symposium PFIZER See detailed programme page 46	Skalkotas Hall
13:00 - 14:00	Satellite Symposium BIOMARIN & SANOFI GENZYME See detailed programme page 46	MC3 Room

ENCA SESSION

14:00 - 14:30	ENCA programme Please refer to page 44 for further details	MC2 Room
---------------	--	----------

POSTER VIEWING

14:00 - 15:00	Poster viewing and poster guided tours Please refer to page 17 for further details	Poster area
---------------	--	-------------

SPECIAL SESSION

14:00 - 15:00	PRINTO / ERN Meeting	
---------------	-----------------------------	--

PReS SESSIONS

15:00 - 17:00	● Autoinflammatory diseases in practice <i>Chairs: Isabelle Kone-Paut (France), Michael Hofer (Switzerland) and Erdal Sag (Turkey)</i>	Banquet Hall
15:00	Clinical presentation and diagnosis of deficiency of adenosine deaminase 2 (DADA2) <i>Seza Ozen (Turkey)</i>	
15:20	New autoinflammatory diseases <i>Joost Frenkel (The Netherlands)</i>	
15:40	Development of classification criteria for autoinflammatory diseases <i>Marco Gattorno (Italy)</i>	
16:00	What's new in the treatment of autoinflammatory diseases <i>Jasmin Kuemmerle-Deschner (Germany)</i>	
16:20	O9 - A web-based collection of genotype-phenotype correlations in hereditary periodic fevers from the Eurofever registry <i>Riccardo Papa (Italy)</i>	
15:00 - 17:00	PReS/ENCA joint session: Parent and child perspectives on physician communication in Pediatric Rheumatology <i>Chairs: Nico Wulffraat (The Netherlands), Pavla Dolezalova (Czech Republic)</i>	Skalkotas Hall
15:00	Introduction of European Network for Children with Arthritis (ENCA) <i>Wendy Costello (Ireland)</i>	
15:15	What is really bothering my patient and his/her parents? - Patient perspective <i>Simon Stones (United Kingdom) & Sarah Dalton (United Kingdom)</i>	
15:40	What is really bothering my patient and his/her parents? - Parent perspective <i>Mirjam Kepic (Slovenia) & Glenda Dalton (United Kingdom)</i>	
16:10	What is really bothering my patient and his/her parents? - Health professional perspective <i>Jan Jaap van der Net (The Netherlands)</i>	
16:30	Insight and recommendations resulting from analysis of parent survey in SHARE project <i>Bas Vastert (The Netherlands) & Tsipi Egert (Israel)</i>	



17:00-17:30 Coffee break

PReS SESSIONS

17:30 - 18:30	State-of-the-art presentations	Banquet Hall
	<i>Chairs: Hermine Brunner (USA), Gerd Horneff (Germany)</i>	
17:30	Familial Mediterranean fever and Adamantiades-Behçet's Disease: Common features and differences <i>Petros P. Sfikakis (Greece)</i>	
18:00	New therapies pipeline for juvenile idiopathic arthritis (JIA) <i>Nicolino Ruperto (Italy)</i>	
17:30 - 19:00	Genetic aspects of pediatric rheumatic diseases	Skalkotas Hall
	<i>Chairs: Carine Wouters (Belgium), Pierre Quartier (France)</i>	
17:30	Genetic heterogeneity of juvenile idiopathic arthritis (JIA) <i>Michael Ombrello (USA)</i>	
17:50	Autoimmune and inflammatory manifestations in patients with primary immunodeficiencies and implications for targeted therapeutics <i>Tadej Avcin (Slovenia)</i>	
18:10	Type I interferonopathies in pediatric rheumatology <i>Nicolas Manel (France)</i>	
18:30	Phenotypes of monogenic systemic lupus erythematosus (SLE) <i>Alexandre Belot (France)</i>	
18:50	O10 - IKZF1 mutation underlines the B cell landscape heterogeneity in mendelian lupus <i>Cécile Frachette (France)</i>	

POSTER GUIDED TOURS

Autoinflammatory diseases

Moderator: Marco Gattorno (Italy)

- P1** PFAPA SYNDROME IN LARGE PEDIATRIC POPULATION: A SINGLE CENTER EXPERIENCE / E. Pehlivan - A. Adrovic* - S. Sahin - K. Barut - O. Kul - O. Kasapcopur
- P2** THROUGH NEW CLASSIFICATION CRITERIA FOR INHERITED PERIODIC FEVERS AND PFAPA. AN INTEGRATED APPROACH AMONG CLINICIANS AND GENETICISTS. / S. Federici* - F. Vanoni - F. Bovis - M. P. Sormani - N. Ruperto - M. Gattorno on behalf of the Expert Committee for the Classification Criteria in periodic fever
- P3** CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: CASE REPORT / M. F. Gicchino* - M. Diplomatico - D. Capalbo - C. Granato - A. N. Olivieri
- P4** PLURIPOTENT STEM CELL MODELS OF BLAU SYNDROME REVEAL AN IFN- γ -DEPENDENT INFLAMMATORY RESPONSE IN MACROPHAGES / Y. Kawasaki* - S. Takada - N. Kambe - R. Nishikomori - T. Nakahata - M. K. Saito
- P5** TRANSCRIPTIONAL REGULATORY GENE VARIATIONS COULD INFLUENCE EXPRESSION PATTERNS AND INFLAMMATORY PROPAGATION IN CLAVICULAR CORTICAL HYPEROSTOSIS / L. Lamot* - K. Gotovac Jercic - A. Blazekovic - M. Vidovic - M. Lamot - F. Borovecki - M. Harjacek
- P6** A NOVEL PHENOTYPE ASSOCIATED WITH ADAM17 MUTATIONS / S. Melo Gomes* - E. Omoyinmi - Y. Hong - G. Anderson - W. Mufzud - W. Moore - C. Edelsten - L. Wilson - P. Brogan
- P7** THE IMPACT OF GASTROINTESTINAL CLINICAL MANIFESTATIONS IN AUTOINFLAMMATORY DISEASES (AID): LESSONS FROM THE INTERNATIONAL EUROFEVER REGISTRY / A. Omenetti* - F. Bovis - J. Frenkel - H. J. Lachmann - S. Ozen - N. Ruperto - M. Gattorno
- P8** NEXT GENERATION SEQUENCING-BASED PANEL SCREENING IN PATIENTS WITH UNDIFFERENTIATED AUTOINFLAMMATORY DISEASES: FRIEND OR FOE? / R. Papa* - M. Rusmini - S. Volpi - A. Grossi - F. Caroli - R. Caorsi - S. Federici - M. Finetti - R. Ravazzolo - I. Ceccherini - M. Gattorno
- P9** MONOGENIC DISEASES MASQUERADING AS BEHÇET'S DISEASE IN THE YOUNG / C. Papadopoulou* - E. Omoyinmi - A. Standing - J. Macwilliam - C. Pain - D. Eleftheriou - P. Brogan

- P10** PROTEOMIC PROFILE OF PATIENTS WITH DIFFERENT AUTOINFLAMMATORY DISEASES: AN APPROACH TO IDENTIFY NEW BIOMARKERS / *F. Penco** - A. Petretto - C. Lavarello - E. Inglese - I. Gueli - A. Omenetti - M. Finetti - F. Tomasi - A. Barla - A. Bertoni - C. Pastorino - M. Gattorno
- P11** THROUGH NEW CLASSIFICATION CRITERIA FOR INHERITED PERIODIC FEVERS AND PFAPA SYNDROME: THE PATIENT VALIDATION PHASE / *F. Vanoni** - S. Federici - F. Bovis - M. Sormani - N. Ruperto - M. Gattorno - M. Hofer on behalf of the Expert Committee for the Classification Criteria in periodic fever

Imaging - Vasculitides

Moderator: Despina Eleftheriou (United Kingdom)

- P46** HENOCHE SCHONLEIN PURPURA NEPHITIS: INITIAL RISK FACTOR AND OUTCOMES IN A TERTIARY CENTER OF LATIN AMERICA / *I. M. Buscatti** - B. B. Casella - N. E. Aikawa - A. Watanabe - S. C. Fahrat - L. M. Campos - C. A. Silva
- P47** TOWARD THE DEVELOPMENT OF A NEW RADIOGRAPHIC SCORE FOR DIAGNOSIS AND MONITORING OF TEMPOROMANDIBULAR JOINT DISEASE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *G. Giancane** - G. Chiappe - F. Sertorio - V. Incarbone - A. Consolaro - N. Laffi - G. M. Magnano - A. Ravelli
- P48** DETERMINING DISEASE ACTIVITY IN CIA BY OPTICAL IMAGING OF PHAGOCYTE MIGRATION. / *S. Gran** - L. Honold - O. Fehler - S. Zenker - S. Hermann - M. Schäfers - T. Vogl - J. Roth
- P49** JUVENILE SJÖGREN'S SYNDROME (JSS): COMPARING GLANDULAR ULTRASOUND IN PRIMARY AND SECONDARY JSS / *J.-P. Haas* - M. Krumrey-Langkammerer*
- P50** TOWARD THE ACHIEVEMENT OF AN AGREEMENT BETWEEN CLINICAL AND ULTRASOUND ASSESSMENT OF THE ANKLE REGION / *S. Lanni** - A. Alongi - A. Civino - A. Consolaro - G. Filocamo - A. Ravelli
- P51** KAWASAKI DISEASE: INITIAL ECHOCARDIOGRAM PREDICTS SUBSEQUENT CORONARY DISEASE AND IMMUNOGLOBULINE RESISTANCE / *D. Chbeir* - J. Gaschinard - R. Bonnefoy - C. Beyler - I. Melki - A. Faye - U. Meinzer*
- P52** CHILDHOOD-ONSET TAKAYASU ARTERITIS: A REFERRAL CENTER EXPERIENCE IN TURKEY / *S. Sahin** - D. Hopurcuoglu - S. Bektas - E. Belhan - A. Adrovic - K. Barut - N. Canpolat - S. Caliskan - L. Sever - O. Kasapcopur
- P53** LOW DOSE CT CORONARY ANGIOGRAPHY AND CALCIUM SCORING IN PATIENTS WITH KAWASAKI DISEASE IN CONVALESCENT PHASE- A PRELIMINARY STUDY / *R. Chakraborty* - S. Singh* - M. Singhal - D. Suri
- P54** LOW DOSE DUAL SOURCE CT CORONARY ANGIOGRAPHY AND CALCIUM SCORING IN CHILDREN WITH KAWASAKI DISEASE NOT TREATED WITH INTRAVENOUS IMMUNOGLOBULIN- A PRELIMINARY STUDY / *S. Dusad* - S. Singh* - M. Singhal - D. Suri
- P55** FLOW MEDIATED DILATATION OF BRACHIAL ARTERY DURING THE ACUTE AND CONVALESCENT STAGES OF KAWASAKI DISEASE-A PRELIMINARY STUDY / *S. Kumar* - S. Singh* - M. Singhal - V. Kumar - D. Suri
- P56** DISCREPANCIES BETWEEN CLINICAL ASSESSMENT AND MR IMAGING IN JIA / *E. C. van Gulik** - R. Hemke - M. M. Welsink-Karssies - D. Schonenberg - K. M. Dolman - A. M. Barendregt - C. M. Nusman - T. W. Kuijpers - M. Maas - J. M. van den Berg
- P57** FLOW CYTOMETRY BASED ASSAY OF PLATELET REACTIVITY IN CHILDREN WITH KAWASAKI DISEASE- A PRELIMINARY STUDY / *P. Vignesh** - S. Singh - A. Rawat - M. U. S. Sachdeva - J. Ahluwalia

Juvenile idiopathic arthritis in practice

Moderator: Olga Vougiouka (Greece)

- P60** THE EFFECT OF TASK-ORIENTED TRAINING WITH VIDEO-BASED GAMES ON ACTIVITY PERFORMANCE AND PARTICIPATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *N. Arman** - E. Tarakci - D. Tarakci - O. Kasapcopur
- P62** VACCINATION COVERAGE IN CHILDREN WITH RHEUMATIC DISEASES / *M. Bizjak** - T. Avčn - N. Toplak
- P63** QUALITY OF REFERRAL LETTERS TO PEDIATRIC RHEUMATOLOGY AND ITS IMPACT ON ACCESS TO CARE / *A. Rydz* - F. Fu - M. Drew - D. Rumsey - Y. Yuan - M. O. Chan*
- P65** EVALUATION OF THE DIAGNOSTIC DELAY AND ACCESS TO REMISSION IN JIA PATIENTS OF THE JIR COHORTE / *C. Freychet** - N. Cabrera - L. Jean Christophe - M. Hofer - A. Belot on behalf of JIR Cohorte
- P66** PERFORMANCE OF DISEASE ACTIVITY MEASURES IN PEDIATRIC PATIENTS WITH ENTHESITIS-RELATED ARTHRITIS / *R. Burgos-Vargas* - G. Horneff - S. M. Tse - P. Quartier* - K. Unnebrink - J. K. Anderson

- P67** TEACHING ADULT RHEUMATOLOGY FELLOWS TO HELP YOUNG ADULT PATIENTS 'STICK THE LANDING' WHEN TRANSFERRING FROM PEDIATRIC TO ADULT RHEUMATOLOGY CARE / *R. E. Sadun* - G. R. Maslow - L. G. Criscione-Schreiber*
- P68** NO RADIOGRAPHIC DAMAGE AFTER EARLY AGGRESSIVE TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS / *D. Schreurs* - W. van Braak - P. Hissink Muller - C. Nusman*
- P69** THE CHARACTERISTIC OF THE UNDIFFERENTIATED ARTHRITIS IN JUVENILE IDIOPATHIC ARTHRITIS / *B. Sozeri* - E. Topaktas - D. Kurtulus*

Juvenile idiopathic arthritis

Moderator: Nico Wulfraat (The Netherlands)

- P70** TIME OF ONSET OF OCULAR DISEASE IN 336 CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS: EVIDENCE-BASED DATA TO REFINE CURRENT OPHTHALMOLOGIC SCREENING GUIDELINES / *S. Calandra* - V. Muratore - V. Ravaschio - G. Giancane - A. Alongi - A. Pistorio - A. Consolaro - A. Ravelli*
- P71** AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN PEDIATRIC PATIENTS WITH EXTENDED OLIGO, ENTHESITIS RELATED, AND PSORIATIC JIA: 6-YEAR DATA FROM THE CLIPPER STUDIES / *I. Foeldvari* - T. Constantin - J. Vojinovic - G. Horneff - J. Dehoorne - G. Susic - K. Kobusinska - V. Panaviene - Z. Zuber - V. Stanevica - V. Chasnyk - R. Pedersen - J. Bukowski - T. Hinnershitz - B. Vlahos - A. Martini - N. Ruperto*
- P72** SUCCESSFUL TREATMENT OF METHOTREXATE INTOLERANCE IN JUVENILE IDIOPATHIC ARTHRITIS USING EYE MOVEMENT DESENSITIZATION AND REPROCESSING (EMDR) / *J.-P. Haas* - L. Höfel - B. Eppler - E. Schnöbel-Müller - B. Hügler*
- P73** THE COMPARISON CHARACTERISTIC BETWEEN PATIENTS WITH SYSTEMIC ONSET OF JUVENILE IDIOPATHIC ARTHRITIS WITH AND WITHOUT LUNG INVOLVEMENT. / *M. M. Kostik* - E. Isupova - I. Chikova - M. Dubko - V. Masalova - L. Snegireva - O. Kopchak - T. Kornishina - N. Abramova - M. Rumyantseva - D. Dzhilkaidarova - M. Kaneva - O. Kalashnikova - V. Chasnyk*
- P74** DECREASING PREVALENCE OF UVEITIS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS SEEN OVER A 30-YEAR PERIOD / *V. Ravaschio* - V. Muratore - S. Calandra - G. Giancane - A. Alongi - A. Pistorio - A. Consolaro - B. Schiappapietra - A. Ravelli*
- P75** COMPARISON OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER ACCOMPANIED WITH SACROILIITIS AND PATIENTS WITH JUVENILE SPONDYLOARTHROPATHY / *H. E. Sönmez* - E. D. Batu - S. Demir - Y. Bilginer - S. Özen*
- P76** EPIDEMIOLOGY, CLINICAL MANIFESTATIONS AND TREATMENT OF SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (SOJIA): A MULTICENTRIC STUDY THROUGH THE INTERNATIONAL PLATFORM JIRCOHORTE. / *K. Theodoropoulou* - A. Belot - V. Hentgen - I. Kone-Paut - C. Wouters - K. Bouayed - E. Cannizzaro - A. Carbasse - E. Merlin - C. Ballot - D. Kaiser - P. Pillet - A. Woerner - W. Bär - S. Poignant - V. Despert - C. Freychet - G. Berthet - L. Higel - T. Tran - F. Vanoni - S. Georgin-Lavialle - M. Hofer*
- P77** AUTOINFLAMMATORY MECHANISMS VIA NF-KB AND CASPASE-1/IL-1 INFLAMMASOME PATHWAYS IN ANA NEGATIVE JUVENILE IDIOPATHIC ARTHRITIS / *A. Zacarias* - A. Mensa - E. Iglesias - R. Bou - J. Calzada - J. Anton - J. I. Arostegui - J. M. Mosquera - V. Bittermann*

Systemic lupus erythematosus

Moderator: TBC

- P124** EMERGING ROLE FOR THE RENAL GLOMERULAR ENDOTHELIAL CELLS AS POTENT INFLAMMATORY CONTRIBUTORS IN JUVENILE-ONSET LUPUS NEPHRITIS / *P. Dimou* - M. Peak - A. Midgley - S. C. Satchell - R. D. Wright - M. W. Beresford*
- P125** COMPARISON OF CLINICAL AND SEROLOGICAL FEATURES OF JUVENILE AND ADULT-ONSET NEUROPSYCHIATRIC LUPUS IN SPANISH PATIENTS / *S. Garrote Corral* - A. García Fernández - W. A. Sifuentes Giraldo - A. L. Boteanu - M. L. Gámir Gámir - A. Zea Mendoza*
- P126** CYTOKINE PROFILE AND EXPRESSION OF STAT1 AND STAT5 IN PERIPHERAL BLOOD IN PATIENTS WITH CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / *M. Holcar* - A. Goropevšek - T. Avčín*
- P127** THE EXPRESSION OF IFN RECEPTOR CHAINS ON NAÏVE AND PRIMED NEUTROPHILS / *S. Irwin* - A. Midgley - M. Peak - M. Beresford*

- P128** C1Q-DEFICIENCY LUPUS TREATED SUCCESSFULLY WITH FRESH FROZEN PLASMA IN A SIBLING PAIR: FIRST DESCRIPTION OF THIS NOVEL THERAPY IN PAEDIATRIC PATIENTS / *R. A. James** - *Y. Glackin* - *C. A. Pilkington*
- P129** CHILDHOOD LUPUS GLOMERULONEPHRITIS OUTCOME IS ASSOCIATED WITH LOW C3 LEVELS AND ANTI-DNA ANTIBODIES AT DISEASE ONSET / *C. S. Magalhaes** - *D. F. Miguel* - *L. G. Portasio* - *J. E. Corrente* - *G. F. Novak* - *B. Molinari* - *A. P. Sakamoto* - *R. R. Pereira* - *T. Terreri* - *E. Bonfa* - *L. A. Campos* - *S. Appenzeller* - *C. A. Len* - *C. A. Silva*
- P131** FEATURES OF 1,555 CHILDHOOD-ONSET LUPUS IN THREE GROUPS BASED ON DISTINCT TIME INTERVALS TO DISEASE DIAGNOSIS: A BRAZILIAN MULTICENTER STUDY / *G. V. Novak** - *B. C. Molinari* - *A. P. Sakamoto* - *M. T. Terreri* - *R. M. Pereira* - *C. Saad-Magalhães* - *N. E. Aikawa* - *L. M. Campos* - *C. A. Len* - *S. Appenzeller* - *V. P. Ferriani* - *M. F. Silva* - *S. K. Oliveira* - *A. G. Islabão* - *F. R. Sztajnbock* - *L. B. Paim* - *C. M. Barbosa* - *M. C. Santos* - *B. E. Bica* - *E. G. Sena* - *A. J. Moraes* - *A. M. Rolim* - *P. F. Spelling* - *I. M. Scheibel* - *A. S. Cavalcanti* - *E. N. Matos* - *T. C. Robazzi* - *L. J. Guimarães* - *F. P. Santos* - *C. T. Silva* - *E. Bonfá* - *C. A. Silva*
- P132** ADULT OUTCOMES IN A LARGE COHORT OF CHILDHOOD-ONSET SLE PATIENTS: COPING AND RESILIENCE IN RELATION TO HEALTH-RELATED QUALITY OF LIFE - THE CHILL-NL STUDY / *R. A. S. Ramnath** - *N. Groot* - *A. Kaynak* - *M. Bijl* - *R. J. M. Dolhain* - *Y. O. Teng* - *E. Zirkzee* - *K. de Leeuw* - *R. Fritsch-Stork* - *I. Bultink* - *S. S. M. Kamphuis*
- P133** UNDERSTANDING THE IMMUNOPATHOGENESIS OF JUVENILE-ONSET SLE USING IMMUNE AND METABOLIC PHENOTYPING / *G. Robinson** - *M. Adriani* - *I. Pineda Torra* - *Y. Ioannou* - *E. Jury on behalf of Jury Group*
- P134** HEPATITIS A VIRUS VACCINATION IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / *S. Mertoglu* - *S. Sahin** - *O. F. Beser* - *A. Adrovic* - *P. Yuksel* - *S. Sazak* - *B. S. Kocazeybek* - *O. Kasapcopur*
- P135** MICROANGIOPATHY IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS, A DETAILED FURTHER QUANTITATIVE ANALYSIS OF CAPILLAROSCOPY ABNORMALITIES / *D. Schonenberg-Meinema** - *J. vd Berg* - *A. Nassar-Sheikh-Rashid* - *G. de Bree* - *A. Hak* - *M. van Onna* - *K. Melsens* - *M. Cutolo* - *T. Kuijpers* - *V. Smith on behalf of EULAR study group on microcirculation in rheumatic diseases*
- P136** TIMING OF INTRAVENOUS CYCLOPHOSPHAMIDE AND LONG-TERM OUTCOME IN CHILDREN WITH PROLIFERATIVE LUPUS NEPHRITIS / *T. Tsuchida** - *A. Ohara* - *K. Nishimura* - *T. Nozawa* - *R. Hara* - *S. Ito*
- P137** SEXUAL DIFFERENCES IN TLR7 DRIVEN INTERFERON ALPHA PRODUCTION MAY EXPLAIN THE INCREASED PREVALENCE OF JSLE IN FEMALES AFTER PUBERTY / *K. Webb** - *G. Butler* - *M. Menon* - *H. Peckham* - *A. Radziszewska* - *L. R. Wedderburn* - *Y. Ioannou*

POSTER VIEWING

Autoinflammatory diseases

- P12** A PRELIMINARY STUDY REGARDING TO THE LEVELS OF VITAMIN B12 AND FOLATE DURING COLCHICINE TREATMENT IN CHILDREN WITH FMF / *Ö. Kaba - M. Çakan - S. G. Karadag - B. Sözeri - G. Keskindemirci - N. Aktay Ayaz**
- P13** LONGITUDINAL ASSESSMENT OF IRON HOMEOSTASIS IN PATIENTS WITH NEWLY DIAGNOSED FAMILIAL MEDITERRANEAN FEVER / *Ö. Kaba - N. Aktay Ayaz* - S. G. Karadag - M. Çakan*
- P14** POPULATION BASED STUDY OF FREQUENCY OF CARRYING FMF MUTATION AMONG ARMENIAN FEMALES / *A. Tadevosyan - T. Avagyan* - G. Amaryan - H. Hayrapetyan - A. Budumyan*
- P15** IS ROUTINE PERIODIC LABORATORY WORK-UP NECESSARY FOR PAEDIATRIC MEFV (MEDITERRANEAN FEVER) CARRIERS / *B. Balahan* - N. Gülez*
- P16** INCREASED PSORIASIS FREQUENCY IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / *E. D. Batu* - A. Erden - E. Seyhoglu - A. Sari - H. E. Sönmez - B. Armagan - S. Demir - E. Bilgin - L. Kılıç - Ö. Karadag - A. Akdgan - Y. Bilginer - I. Ertenli - S. Kiraz - S. A. Bilgen - U. Kalyoncu - S. Özen*
- P17** PERIODIC FEVER, APHTOUS STOMATITIS, PHARYNGITIS AND CERVICAL ADENTITIS (PFAPA) SYNDROME. A QUALITATIVE STUDY OF PARENT'S EXPERIENCES AND STRATEGIES / *C. Sparud-Lundin - S. Berg* - A. Fasth - A. Karlsson - P. Wekell*
- P18** AICARDI-GOUTIÈRES SYNDROME WITH A NOVEL MUTATION IN THE SAMHD1 GENE / *S. Boiu* - A. Nezos - I. Melki - A. Dinopoulos - E. Atsali - C. Mavragani - V. Papaevangelou - D. Boumpas*
- P19** THE CHALLENGES TO DIAGNOSE AND TREAT A RARE PATIENT WITH CANDLE SYNDROME / *M. Boyadzhiev* - V. Boyadzhiev - L. Marinov - V. Iotova - S. Hambleton - I. Aksentijevich*
- P20** COMPLEMENT ENDORSE THE PATHOGENESIS IN AUTOINFLAMMATION / *J. Brunner* - W. Posch - E. Rabensteiner - D. Wilflingseder*
- P21** RECURRENT PERICARDITIS: CLINICAL COURSE AND TREATMENT IN PEDIATRIC PATIENTS / *C. Celani* - D. Khraiche - P. Quartier - D. Bonnet - B. Bader-Meunier*
- P22** SINOGENIC SUBDURAL EMPYEMA IN TWO GIRLS TREATED WITH ADALIMUMAB FOR CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (CRMO) / *A. E. Christensen* - P. Toftedal*
- P23** SPECTRUM OF CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS IN A BELGIAN COHORT OF 25 CHILDREN: CLINICAL PRESENTATION, IMAGING, TREATMENT AND OUTCOME / *L. De Somer* - S. Kaut - I. Van den Wyngaert - D. Christiaens - C. Wouters - S. Pans*
- P24** CLINICAL CHARACTERISTICS OF FAMILIAL MEDITERRANEAN FEVER PATIENTS ACCORDING TO THEIR MEFV MUTATION / *P. Esmeray* - Z. S. Arci - H. E. Sönmez - Y. Bilginer - S. Özen*
- P25** INFECTION STATUS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER (FMF) ACCORDING TO MEFV / *P. Esmeray* - E. D. Batu - Z. S. Arci - H. E. Sönmez - Y. Bilginer - S. Özen*
- P26** CLINICAL CHARACTERISTICS OF FMF PATIENTS ACCORDING TO AGE GROUPS / *P. Esmeray* - E. D. Batu - H. E. Sönmez - S. Demir - Y. Bilginer - S. Özen*
- P27** ORAL FINDINGS IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / *P. Esmeray* - E. D. Batu - Z. S. Arci - T. I. Keçeli - Y. Bilginer - M. Tekçiçek - S. Özen*
- P28** SUCCESSFUL USE OF TOCILIZUMAB, INTERLEUKIN-6 (IL-6) INHIBITOR, IN A CHILD WITH TRAPS / *E. Fedorov* - S. O. Salugina*
- P29** THE EUROFEVER PROJECT: AN UPDATE ON THE LONGITUDINAL STAGE / *M. Finetti* - S. Federici - J. Frenkel - S. Ozen - H. Lachmann - F. De Benedetti - J. Swart - L. Cantarini - R. Gallizzi - M. Cattalini - R. Cimaz - D. Rigante - J. Anton - M. Alessio - A. N. Olivieri - P. Dolezalova - A. Jansson - G. Fabio - J. Sanchez Manubens - E. Hachulla - R. Consolini - K. Krause - Z. Ekinci - J. Brunner - I. Koné-Paut - G. Filocamo - M. D. C. Pinedo - E. Papadopoulou-Alataki - L. Bezrodnik - A. Martini - N. Ruperto - M. Gattorno on behalf of on behalf of Eurofever Project*
- P30** MEVALONATE-KINASE DEFICIENCY IN THE CZECH REPUBLIC / *S. Fingerhutova* - L. Dvorakova - P. Chrastina - A. Klocperk - P. Keslova - E. Jancova - M. Schuller - A. Kolsky - Z. Lucakova - P. Dolezalova*
- P31** EYE MANIFESTATIONS OF PATIENTS WITH MUCKLE-WELLS SYNDROME / *S. Cekic - O. Yalcinbayir - S. S. Kilic**
- P32** CLINICAL COMPARISON OF PATIENTS WITH UNIFOCAL AND MULTIFOCAL CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS IN AN IRISH COHORT / *D. O'Leary - A. G. Wilson - E.-J. MacDermott - O. Killeen**

Bone in rheumatic diseases

- P34** PERFORMANCE OF BONE SCAN COMPARED TO WHOLE BODY-MRI IN EVALUATION OF CHRONIC NON-BACTERIAL OSTEOMYELITIS / *P. L. Ooi** - *G. Buckley* - *L. Biassoni* - *M. Easty* - *S. Compeyrot-Lacassagne*
- P35** THE STATUS OF BONE METABOLISM IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *Y. M. Spivakovskiy** - *A. Spivakovskaja* - *Y. Chernenkov* - *N. Zacharova*
- P36** TOCILIZUMAB (ANTI-IL6R MOAB) ACHIEVES COMPLETE AND SUSTAINED REMISSION IN A PATIENT WITH REFRACTORY CRMO / *E. Van Nieuwenhove** - *L. De Somer* - *N. Noppe* - *S. Pans* - *C. Wouters*

Disease outcome

- P37** INTRAARTICULAR CORTICOSTEROID INJECTIONS (IACI) OF TEMPORO-MANDIBULAR JOINTS (TMJ) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): THE PATIENTS' PERSPECTIVE / *A. Arduini** - *D. Pires-Marafo* - *R. Nicolai* - *A. Pucacco* - *F. De Benedetti* - *S. Magni-Manzoni*
- P38** EARLY PAIN REPORT IN OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IS RELATED TO LONG-TERM OUTCOME / *E. D. Arnstad** - *V. G. Rypdal* - *S. Peltoniemi* - *E. Nordal* - *L. Berntson* - *K. Aalto* - *A. Fasth* - *T. Herlin* - *S. Nielsen* - *M. Zak* - *P. R. Romundstad* - *M. Rygg* on behalf of Nordic Study Group of Pediatric Rheumatology (NoSPeR)
- P39** HLA II CLASS ALLELES IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS WITH AND WITHOUT CHRONIC ARTHRITIS SIGNS IN TEMPOROMANDIBULAR JOINTS EVALUATED WITH CONTRAST ENHANCED MRI / *Z. Davidsons** - *E. Eglite* - *A. Kolesovs* - *R. Santere* - *V. Stanevica*
- P40** THE ROLE OF ANTINUCLEAR ANTIBODIES POSITIVITY IN PREDICTING CLINICAL REMISSION IN JUVENILE IDIOPATHIC ARTHRITIS / *R. M. Ferreira** - *F. Aguiar* - *M. Rodrigues* - *I. Brito*
- P41** EVALUATION OF KNEE JOINT Q ANGLE AND BALANCE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS WITH PES PLANOVALGUS DEFORMITY / *E. P. Kisa** - *S. Inal* - *E. Tarakci* - *N. Arman* - *O. Kasapcopur*
- P42** DEVELOPMENT OF A UNIQUE PLATFORM FOR PEDIATRIC IMMUNO-RHEUMATOLOGIC DISEASES (JIRCOHORTE): INCLUSION OF 3266 PATIENTS. / *M. Mejri** - *R. Carlomagno* - *F. Hofer* - *V. Hentgen* - *B. Bader-Meunier* - *B. Fonjallaz* - *S. Georgin-Lavialle* - *Y. Guex-Crosier* - *P. Scolozzi* - *A. Woerner* - *E. Cannizzaro* - *D. Kaiser* - *G. Berthet* - *W. Baer* - *F. Vanoni* - *K. Theodoropoulou* - *A. Belot* - *M. Hofer*

Genetics and environment

- P43** PROGRESSIVE PSEUDORHEUMATOID DYSPLASIA RESOLVED BY WHOLE EXOME SEQUENCING: A NOVEL MUTATION IN WISP3 AND REVIEW OF THE LITERATURE / *A. Elyahu** - *B. Pode-Shakked* - *A. Vivante* - *O. Barel* - *S. Padeh* - *D. Marel-Yagel* - *A. Veber* - *S. Abudi* - *I. Tirosh* - *S. Shpilman* - *S. Shril* - *G. Rechavi* - *F. Hildebrandt* - *M. Shohat* - *Y. Anikster*
- P44** CYTOKINES GENES AND THE SEVERITY OF JUVENILE IDIOPATHIC ARTHRITIS / *L. S. Nazarova* - *K. V. Danilko* - *T. V. Viktorova* - *V. A. Malievsky**
- P45** SINGLE NUCLEOTIDE POLYMORPHISMS IN SURVIVIN GENE ARE ASSOCIATED TO RESPONSE TO METHOTREXATE IN JUVENILE IDIOPATHIC ARTHRITIS / *M. Zajc Avramovič** - *V. Dolzan* - *N. Toplak* - *T. Avcin*

Immunodeficiency and infection related arthritis

- P58** DEFICIENCY OF CD70 IS RESPONSIBLE OF A CASE OF CHRONIC ACTIVE EBV (CAEBV) INFECTION PRESENTING AS PERIODIC FEVER / *R. Caorsi** - *M. Rusmini* - *S. Volpi* - *S. Chiesa* - *C. Pastorino* - *F. Minoia* - *A. Grossi* - *S. Signa* - *P. Picco* - *A. Ravelli* - *I. Ceccherini* - *M. Gattorno*
- P59** CLOSTRIDIUM DIFFICILE ENTEROCOLITIS AND REACTIVE ARTHRITIS: A CASE REPORT AND RE-VIEW OF THE LITERATURE / *L. Mambelli** - *M. Cappella* - *M. Mainetti* - *F. Marchetti*

Juvenile idiopathic arthritis (oligo, poly, psoriatic)

- O2** PERSISTENCE OF CD4 MEMORY PATHOGENIC SUBSETS IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS PATIENTS WHO RELAPSE UPON WITHDRAWAL OF BIOLOGIC THERAPY / *J. Y. Leong* - *J. G. Yeo* - *P. Chen* - *L. Lai* - *L. D/O Thana Bathi* - *J. Tan* - *T. Arkachaisri* - *D. J. Lovell* - *S. Albani*
- P78** THE LULL BEFORE THE TMJ STORM: IDENTIFYING A WINDOW OF OPPORTUNITY FOR EARLY IDENTIFICATION OF TMJ ARTHROPATHY / *C. M. Adams** - *C. Pilkington*

- P79** BURDEN OF DISEASE IN THE PEDIATRIC RHEUMATOLOGY CLINIC AT ALAIN HOSPITAL: THE UAE EXPERIENCE / *A. A. Alhosani**
- P80** INVESTIGATING LONGITUDINAL COURSE OF ANKLE INVOLVEMENT IN RELATION TO TREATMENT IN CHILDREN WITH JIA USING A MULTISTATE MARKOV MODEL APPROACH / *A. Alongi** - *A. Consolaro* - *A. Ravelli*
- P81** NOVEL MUTATIONS IN PRG4 GENE IN ONE GREEK FAMILY WITH CAMPTODACTYLY-ARTHROPATHY-COXA VARA-PERICARDITIS (CACP) SYNDROME / *S. Boiu** - *M. Barat* - *I. Touitou* - *D. Geneviève* - *V. Kontogeorgakos* - *E. Atsali* - *D. Boumpas* - *V. Papaevangelou*
- P82** DENTAL ANXIETY AND ORAL HEALTH IN JUVENILE IDIOPATHIC ARTHRITIS / *C. Boros** - *J. Armfield*
- P83** CHARACTERIZATION OF A COLOMBIAN COHORT WITH JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE MULTICENTER EXPERIENCE / *M. Cañola** - *M. A. Alzate* - *D. Hernandez-Parra* - *D. Echeverry* - *J. C. Uribe-Salazar* - *J. Alvarez* - *L. Londoño* - *P. Ortiz-Salazar* - *R. Pineda*
- P84** EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CLINICAL PRACTICE / *G. Díaz-Cordovés** - *N. Mena* - *E. Nuñez-Cuadros* - *S. Manrique* - *R. Galindo-Zavala*
- P85** FAT MASS IN JUVENILE IDIOPATHIC ARTHRITIS. SHOULD WE THINK ABOUT IT? / *G. Díaz-Cordovés** - *E. Nuñez-Cuadros* - *R. Galindo-Zavala* - *S. Manrique* - *M. Natalia*
- P86** HYPOVITAMINOSIS D IN JUVENILE IDIOPATHIC ARTHRITIS: PREVALENCE AND INVOLVED FACTORS / *R. Galindo Zavala** - *L. Martín Pedraz* - *E. Núñez Cuadros* - *G. Díaz-Cordovés Rego* - *A. L. Urda Cardona*
- P87** NEUROPSYCHOLOGICAL ASSESSMENT IN JUVENILE IDIOPATHIC ARTHRITIS - PART I: CROSS-SECTIONAL STUDY IN A SINGLE HUNGARIAN CENTRE / *D. Garan** - *G. Gergev* - *W. Wijker* - *I. Bozi* - *T. Constantin*
- P88** CHARACTERISTICS OF TNF INHIBITOR TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS - 2-YEAR-FOLLOW-UP IN A HUNGARIAN CENTRE / *D. Garan** - *A. P. Juhász* - *A. Ponyi* - *T. Constantin*
- P89** BODY COMPOSITION MEASURED BY DEXA IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS. DO THEY HAVE SARCOPENIA? / *P. Guarnizo** - *S. Pino* - *A. Diaz-Maldonado* - *J. M. Reyes*
- P90** CLINICAL TMJ INVOLVEMENT IN JIA PATIENTS ACCORDING TO THE ILAR CATEGORIES: PRELIMINARY STUDY IN 137 CHILDREN / *S. Guillaume Czitrom** - *G. De Filippo*
- P91** MRP8/14 AND CONVENTIONAL INFLAMMATORY MARKERS EXPLAINING PHYSICIAN'S GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN NEW-ONSET JUVENILE IDIOPATHIC ARTHRITIC PATIENTS / *P. Keskitalo** - *S. Kangas* - *P. Vähäsalo*
- P92** CHRONIC ARTHRITIS AS THE ONLY MANIFESTATION OF FMF IN ARMENIAN CHILDREN / *G. Khloyan**
- P93** THE EFFICACY OF ETANERCEPT IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN SAINT-PETERSBURG: THE PRELIMINARY DATA OF 148 PATIENTS FROM BIOLOGIC REGISTRY / *M. M. Kostik** - *I. Chikova* - *E. Isupova* - *M. Dubko* - *V. Masalova* - *L. Snegireva* - *E. Gaidar* - *O. Kalashnikova* - *V. Chasnyk*
- P94** THE TREATMENT OF 40 POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS CHILDREN WITH TOCILIZUMAB: SINGLE CENTER EXPERIENCE / *M. M. Kostik** - *I. Chikova* - *E. Isupova* - *M. Dubko* - *V. Masalova* - *L. Snegireva* - *E. Gaidar* - *O. Kalashnikova* - *V. Chasnyk*
- P95** ATYPICAL OLIGOARTICULAR JUVENILE ARTHRITIS IN CHILDREN: ELBOW CHRONIC MONOARTHRITIS / *A. Kozhevnikov** - *N. Pozdeeva* - *M. Konev* - *M. Nikitin* - *A. Bryanskaya* - *E. Prokopovich* - *K. Afonichev* - *G. Novik*
- P96** PLATELET MICROPARTICLES LEVEL IN JUVENILE IDIOPATHIC ARTHRITIS / *S. Kumar** - *N. Kumar*

Miscellaneous rheumatic diseases

- P97** THE NEED FOR DEDICATED PAEDIATRIC RHEUMATOLOGY SERVICES: RETROSPECTIVE REVIEW OF A CLINIC SERVICE AT TYGERBERG HOSPITAL, SOUTH AFRICA / *D. R. Abraham** - *M. M. Esser*
- P99** UNILATERAL RECURRENT EAR CHONDROITIS IN SPONDYLARTHROITIS DOES NOT ALWAYS PROGRESS TO POLYCHONDROITIS / *L. Damian** - *S. Rednic* - *C. Pamfil* - *L. Ghib* - *M.-M. Tamas* - *S.-P. Simon* - *C. Lazar* - *L. Muntean* - *A. Maniu*
- P100** EVALUATION OF THE DENTAL AND TEMPOROMANDIBULAR JOINT STATUS IN CHILDREN WITH GENERALIZED JOINT HYPERMOBILITY / *F. Demir** - *T. Tüzüner* - *Ö. Baygın* - *M. Kalyoncu*
- P101** "SUCCESSFUL TREATMENT OF PEDIATRIC IGG4 RELATED OPHTHALMIC DISEASE WITH MYCOPHENOLATE MOFETIL: CASE REPORT AND A REVIEW OF THE PEDIATRIC AUTOIMMUNE DACRYOADENITIS LITERATURE" / *T. Diaz** - *Y. Ramirez* - *S. Osorio* - *M. T. Braña* - *L. Aparicio* - *A. Rodriguez* - *E. Faugier* - *R. Maldonado*

- P102** RHEUMATIC FEVER AND POST-STREPTOCOCCAL ARTHRITIS IN A TERTIARY HOSPITAL FROM PARAGUAY / *J. Garcete* - L. Galeano - C. Montiel - D. Chin - M. D. C. Cabrera - M. Vargas Peña - C. Verón - M. Lezcano - A. Aldana - A. Campuzano de Rolón - Z. Morel Ayala*
- P103** IMMUNOGLOBULIN THERAPY IN THE TREATMENT OF CEREBRAL CONSEQUENCES OF NEONATAL LUPUS ERYTHEMATOSUS / *K. McLellan* - J. Davidson - M. Ilina - E. Campbell - J. Walsh*
- P104** VALIDITY AND RELIABILITY STUDY FOR THE KOREAN VERSION OF THE HAEMOPHILIA ACTIVITY LIST IN PEDIATRIC AND ADULT PATIENTS WITH HAEMOPHILIC ARTHROPATHY / *S. Park* - H. Lee - J.-Y. Choe*
- P105** INFLAMMATORY PSEUDOTUMOR: T HELPER CELL SUBTYPES AND RELATION TO IGG4-RELATED DISEASE? / *E. Sag* - G. Kale - B. Talim*
- P106** HYPERBARIC OXYGEN THERAPY IN A LIVEDOID VASCULOPATHY: A CASE REPORT / *N. Sahin* - A. Pac Kisaarslan - S. Ozdemir Cicek - B. Sözeri - M. E. Akcin - Z. Gunduz - R. Dusunsel - M. H. Poyrazoglu*
- P107** ECHOCARDIOGRAPHIC FINDINGS IN CHILDREN WITH OSTEOGENESIS IMPERFECTA / *S. Fallah - M. R. Alaei - R. Shiari* - S. Mojtahed Zadeh - B. Sobouti*
- P108** ACID CERAMIDASE DEFICIENCY (FARBER DISEASE) CAUSES SYMPTOMS RESEMBLING JIA AND IS LIKELY UNDERDIAGNOSED: WE PRESENT A UNIQUE CROSS-SECTIONAL NATURAL HISTORY STUDY DESIGN TO ADDRESS THE LACK OF CLINICAL DATA ON THIS RARE DISEASE / *A. Solyom* - B. Hügler - D. Tetzl - E. H. Schuchman*
- P109** INVOLVING PATIENTS, PARENTS AND CARERS IN PAEDIATRIC RHEUMATOLOGY RESEARCH: BEST PRACTICES EXAMPLES FROM LAY REPRESENTATIVES OF THE UNITED KINGDOM'S CLINICAL STUDIES GROUP / *S. R. Stones* - C. Wright*
- P110** DEFINING THE CLINICAL IMPACT OF SYMPTOMS IN A DIVERSE POPULATION OF PATIENTS WITH A RARE DISEASE: A QUALITATIVE RESEARCH STUDY IN ACID CERAMIDASE DEFICIENCY (FARBER DISEASE) / *A. Solyom - B. Johnson - K. Ehlert - D. Tetzl* - K. Coyne*
- P111** A NOVEL HOMOZYGOUS MUTATION OF GENE WISP3 IN PROGRESSIVE PSEUDORHEUMATOID DYSPLASIA / *S. Torreggiani* - M. Torcoletti - G. Di Landro - C. Agostoni - B. Campos-Xavier - A. Superti-Furga - G. Filocamo*
- P112** ASSOCIATION OF JUVENILE-ONSET PRIMARY SJÖGREN SYNDROME WITH TYPE I C2 DEFICIENCY / *E. Van Nieuwenhove* - L. De Somer - C. Wouters*

Psycho-social aspects and rehabilitation

- P113** INTRODUCING RAIISE - RAISING AWARENESS OF INVISIBLE ILLNESSES IN SCHOOLS AND EDUCATION / *S. Ainsworth* - J. Ainsworth - J. Preston - S. Stones - R. Challinor - M. Rowe*
- P114** DEVELOPMENT AND FEASIBILITY OF A SHARED MANAGEMENT TOOL FOR SCHOOL CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *J. H. Cappon* - B. Knoester - M. A. van Rossum*
- P115** A SMILING CHILDHOOD: A SOCIAL WINDOW FOR FAMILIES WITH CHILDREN AFFECTED BY CHRONIC RHEUMATICS AND RARE PATHOLOGIES / *A. Celano* - R. Arnesano - A. Sticchi on behalf of APMAR ONLUS*
- P116** ANXIETY, DEPRESSION, AND PARENTAL PERCEPTION OF UNCERTAINTY AMONG PARENTS OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS IN BOGOTA, COLOMBIA / *A. Diaz-Maldonado* - S. Pino - P. Guarnizo - J. M. Reyes - L. Ariza*
- P117** REHABILITATION GAMES FOR JUVENILE IDIOPATHIC ARTHRITIS. FOCUS ON HAND AND WRIST / *A. Petaccia* - R. M. Chiuri - A. Petaccia - F. Corona - M. Foà - P. L. Lanzi - G. Filocamo*
- P118** REHABILITATION GAMES FOR JUVENILE IDIOPATHIC ARTHRITIS. FOCUS ON KNEE AND ANKLE / *A. Petaccia* - A. Lopopolo - M. Giannotti - F. Corona - P. L. Lanzi - G. Filocamo*
- P119** RECURRENT ARTHRALGIA OR FUNCTIONAL PAIN? EVALUATION OF PSYCHOLOGICAL DISTRESS IN ITALIAN SCHOOL STUDENTS / *M. Lo Curto - M. C. Maggio* - F. Campisi - G. Corsello*
- P120** POSTURE AND BALANCE DEFICIT IN CHILDREN WITH JIA: A PILOT STUDY / *A. Patti - G. Corsello - A. Bianco - G. Messina - A. Iovane - A. Palma - J. Brusa - M. C. Maggio**
- P121** IMPROVED TRANSITIONAL PROCESS BY NURSE GUIDED TRANSITION PROGRAM / *K. Mördrup* - A. Vermé*
- P122** TRANSITION IN RHEUMATOLOGY- 5 YEAR EXPERIENCE / *M. Šenjug Perica* - M. Mayer - M. Vidovi - L. Lamot - M. Harjaček - L. Tambić Bukovac*
- P123** THE PSYCHOMOTOR EFFECT OF AN ORGANIZED SUMMER CAMP PROGRAM ON CHILDREN WITH RHEUMATIC DISEASES: A 5 YEAR EVALUATION / *M. Stavrakidou* - K. Spanidou - P. Pratsidou-Gertsis - A. Koutsonikoli - F. Kanakoudi-Tsakalidou*

Systemic lupus erythematosus and antiphospholipid syndrome

- O3** A MULTI-DIMENSIONAL IMMUNOMICS APPROACH REVEALS DISTINCT REGULATORY AND ANTIGEN PRESENTING B CELL CHANGES ASSOCIATED WITH CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / J. G. Yeo - J. Leong - T. Arkachaisri - A. Y. J. Tan - L. D. Thana Bathi - X. Sim - P. Z. X. Chen - L. Lai - L. Das - J. H. T. Tan - E. S. C. Lee - Y. X. Book - S. Albani
- P138** SIMILARITIES AND DIFFERENCES BETWEEN CHILDHOOD-ONSET AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS IN SULTANATE OF OMAN / A. Al Rasbi - R. Sultan - N. Abdallah - J. Al Kaabi - R. Abdwani*
- P139** NEONATAL LUPUS ERYTHEMATOSUS: A 12-YEAR RETROSPECTIVE STUDY IN KOREA / J. G. Ahn* - D. S. Kim - Y. D. Kim - K. N. Kim
- P140** ANALYSIS OF MEFV GENE SEQUENCE VARIANTS AND ASSOCIATION WITH CLINICAL FEATURES AND DISEASE ACTIVITY IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / A. Zopçuk - N. Aktay Ayaz* - B. Sözeri - M. Çakan - S. G. Karadağ - A. Paç Kısaarslan - Z. Gündüz
- P141** EPIDEMIOLOGY, CLINICAL CHARACTERISTICS AND THERAPY APPROACHES OF A RETROSPECTIVE COHORT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY CENTRE / R. M. Alcobendas* - S. Murias - A. Remesal - A. Munoz Calongue
- P142** HISTOLOGICAL GRADING OF LUPUS NEPHRITIS IS RELATED TO EARLY CHANGE IN GROWTH PARAMETERS / Y. A. Arguello* - G. Filocamo - S. Torreggiani - V. Litta Modigliani - G. Marisa - G. Montini
- P143** IS ABNORMALITY OF LIPID PROFILE ASSOCIATED WITH MORE SEVERE HISTOLOGICAL FINDINGS AT RENAL BIOPSY IN CHILDREN WITH LUPUS NEPHRITIS ? / F. Baldo* - V. Litta-Modignani - S. Torreggiani - C. V. Agostoni - M. Giani - G. Montini - G. Filocamo
- P144** CLINICAL AND IMMUNOLOGICAL CHARACTERISTICS OF CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS TREATED WITH RITUXIMAB / A. L. Boteanu* - M. A. Blazquez Cañamero - A. Alia Jimenez - S. Garrote Corral - M. J. García Villanueva - M. Gamir Gamir
- P145** PANNICULITIS IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTRIC COHORT STUDY / L. M. Campos* - M. Verdier - P. Anuardo - N. Gormezano - R. Romiti - N. Aikawa - R. Pereira - M. T. Terreri - C. Magalhães - J. Ferreira - M. Silva - M. Ferriani - A. P. Sakamoto - V. Ferriani - M. Centeville - J. Sato - M. C. Santos - E. Bonfá - C. Silva
- P146** PREVALENCE OF ENA AND ANTI CARDIOLIPIN ANTIBODIES IN DIFFERENT CLASSES OF LUPUS NEPHRITIS / G. Di Landro* - F. Baldo - V. Litta Modignani - M. Giani - G. Montini - C. V. Agostoni - G. Filocamo
- P147** JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL AND IMMUNOLOGICAL PATTERNS OF DISEASE EXPRESSION IN A COHORT OF MEXICAN CHILDREN / S. Osorio - A. Rodríguez - R. Maldonado - E. Faugier - T. Díaz* - Y. Ramirez - L. Aparicio - M. Braña
- P148** NEONATAL LUPUS - CASE SERIES OF A TERTIARY HOSPITAL / A. R. Teixeira - R. Ferreira* - M. Rodrigues - F. Aguiar - I. Brito
- P149** GENDER DIFFERENCES IN SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTATION AND TREATMENT AT PAEDIATRIC RHEUMATOLOGY DEPARTMENT, SOFIA, BULGARIA FOR A PERIOD OF 4 YEARS (2013-2017) / M. Ganeva* - S. Stefanov - A. Telcharova - D. Mihaylova - V. Kostova - K. Temelkova - T. Andreeva
- P150** DIFFERENCES OF THE METABOLOME OF AUTOIMMUNE DISEASES / A. E. A. Glaser* - A. Midgley - H. L. Wright - M. M. Phelan - M. Peak - M. W. Beresford
- P151** PRIMARY ANTIPHOSPHOLIPID SYNDROME IN CHILDREN – CASE SERIES FROM CHENNAI, SOUTH INDIA / M. Janarthanan* - D. Vetrichelvan - A. Rajendran - S. Sowdagar - S. Srinivas - M. Saravanan - C. Sundaramoorthy
- P152** NOVEL URINE BIOMARKERS FOR THE ASSESSMENT OF PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS NEPHRITIS / A. Koutsonikoli* - M. Trachana - E. Farmaki - V. Tzimouli - P. Pratsidou-Gertsis - N. Printza - A. Garyphallos - V. Galanopoulou - F. Kanakoudi-Tsakalidou - F. Papachristou

Treatment

- P153** SMART TECHNOLOGIES TO IMPROVE HEALTH OUTCOMES IN JUVENILE IDIOPATHIC ARTHRITIS / A. Coda* - D. Sculley - D. Santos - X. Girones - D. Smith - J. Burns - K. Rome - J. Munro - D. Singh-Grewal
- P154** REDUCED-DOSE RITUXIMAB IN TREATMENT OF PEDIATRIC RHEUMATIC DISEASES / N. E. Rubio-Perez - F. Garcia-Rodriguez* - M. D. Torres-Made - M. E. de la O-Cavazos

- P155** ETANERCEPT (ENBREL®) TREATMENT RETENTION IN THE SUB-POPULATION OF PEDIATRIC PATIENTS FROM A RETROSPECTIVE COHORT STUDY USING CANADIAN CLAIMS-LEVEL DATA / *M. Khraishi* - B. Millson - J. Woolcott - H. Jones - L. Marshall*
- P156** A CASE REPORT OF A PEDIATRIC PATIENT WITH ORBITAL IGG4-RELATED DISEASE / *A. Kozlova* - V. Burlakov - D. Abramov - G. Sagoyan - A. Shcherbina*
- P157** OPTIMUM SERUM ADALIMUMAB LEVELS IN JUVENILE IDIOPATHIC ARTHRITIS ACCORDING TO THE RESPONSE CRITERIA / *B. Lopez* - M. Gonzalez - M. Marti - L. Martinez - S. G. Ceberio - I. Calvo*
- P158** EFFICACY OF OMALIZUMAB TREATMENT IN A GIRL WITH AUTOINFLAMMATORY DISEASE AND CHRONIC URTICARIA / *M. C. Maggio* - A. Lucania - G. Corsello*
- P159** THE USE OF CONSEQUENTIAL BIOLOGIC DMARDS IN PAEDIATRIC RHEUMATOLOGY / *J. Mcallister* - A. Clough - P. Riley - A. Chieng*

Uveitis

- P160** THE PERSISTENCE OF ANA POSITIVE IN JIA PATIENTS AND THE RISK OF DEVELOPING CHRONIC ANTERIOR UVEITIS: A RETROSPECTIVE STUDY / *A. L. Boteanu* - M. Llop Vilaltella - M. A. Terán Tinedo - M. A. Blazquez Cañamero - M. Gamir Gamir*
- P161** UVEITIS ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS: LOWER PREVALENCE AND UNIQUE CLINICAL CHARACTERISTICS IN ASIAN PATIENTS / *P. Chan Ng* - L. K. Lim - E. Y. Ang - P. L. Ooi*
- P162** OUR MODEST EXPERIENCE WITH ADALIMUMAB IN THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS / *A. Ćosićkić* - F. Skokić - S. Suljendić - M. Halilbašić - A. Selimović*
- P163** A RARE CASE OF RECURRENT BILATERAL OPTIC DISC EDEMA IN TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS SYNDROME TREATED WITH INFLIXIMAB / *S. E. Dhaese* - J. Dehoorne - J.-B. Willemot - J. Vande Walle - I. De Schryver*

Vasculitides

- P164** EVALUATION OF CHILDREN WITH BEHÇET'S DISEASE FROM REGIONALLY TWO DIFFERENT CENTERS OF A HIGHLY PREVALENT COUNTRY / *N. Aktay Ayaz* - B. Sözeri - M. Çakan - Z. Gündüz - A. Paç Kısaarslan - R. Düşünsel - H. Poyrazoğlu*
- P165** EVALUATION OF COGNITIVE FUNCTION ELECTROPHYSIOLOGICALLY IN CHILDREN WITH BEHÇET DISEASE / *N. Aktay Ayaz* - G. Eskikurt - G. Keskindemirci - M. Çakan - N. Ermutlu - Ü. İşoğlu Alkaç*
- P166** MEASUREMENT OF THE CAROTID INTIMA MEDIA THICKNESS (CIMT) OF CAROTID ARTERIES IN PEDIATRIC BEHÇET'S DISEASE / *Z. S. Arici* - B. Oğuz - E. D. Batu - H. E. Sönmez - S. Demir - A. Düzova - Y. Bilginer - S. Özen*
- P167** DIFFICULTIES IN DIAGNOSTICS SYSTEMIC CHILDREN'S VASCULITIDES / *O. A. Oshlyanska - A. G. Artsymovych **
- P168** KAWASAKI DISEASE AND GIANT ANEURYSM IN MEXICAN CHILDREN: EVOLUTION AND CLINICAL CHARACTERISTICS: A 5-YEAR EXPERIENCE / *M. T. Brana* - T. Diaz - Y. Ramirez - S. Osorio - L. Aparicio - A. Rodriguez - E. Faugier - R. Maldonado*
- P169** SCROTAL INVOLVEMENT IN CHILDREN AND ADOLESCENTS HENOC SCHONLEIN PURPURA / *I. M. Buscatti* - H. M. Abrão - K. Kozu - V. V. Marques - R. Cunha - A. M. Sallum - C. A. Silva*
- P170** RENAL INVOLVEMENT IN HENOC-SCHONLEIN PURPURA; POSSIBLE CORRELATION OF POSITIVE ANTIPHOSPHOLIPID ANTIBODIES / *M. Hassas Yeganeh* - K. Rahmani - A. Yaraghi*
- P171** "ECZEMA" WITH EOSINOPHILIA AND RAISED IGE: IS IT EOSINOPHILIC GRANULOMATOSIS AND POLYANGIITIS (EGPA)? / *A. C. H. Ho* - C. M. Chow*
- P172** CHILDHOOD TAKAYASU ARTERITIS WITH DRUG RESISTANT TUBERCULOUS LYMPHADENITIS / *M. Janarthanan* - P. Venkatramanan - V. Krishna - T. Arunprasath - B. Rajesh*

SATURDAY 16 SEPTEMBER

SCIENTIFIC SESSIONS

PRoS SESSIONS

08:30 - 09:00 **A year in review: Clinical and health sciences** **Banquet Hall**
Chairs: Angelo Ravelli (Italy), Jelena Vojinovic (Serbia)
Speaker: Joost Swart (The Netherlands)

09:00 - 10:30 **● Remission in chronic arthritis** **Banquet Hall**
Chairs: Angelo Ravelli (Italy), Jelena Vojinovic (Serbia) and Dragana Lazarevic (Serbia)

09:00 **Lessons from early arthritis studies and animal models**
Joao Fonseca (Portugal)

09:20 **Is sustained remission a realistic goal in JIA? Real-world data from patient registries**
Gerd Horneff (Germany)

09:40 **Biologic markers as indicators of disease remission**
Dirk Foell (Germany)

10:00 **Role of imaging in assessment of disease remission**
Clara Malattia (Italy)

10:20 **O11 - Development of new JADAS and CJADAS cut-offs for disease activity states in oligoarthritis and RF-negative polyarthritis from a large multinational cohort of children with juvenile idiopathic arthritis**
Alessandro Consolaro (Italy)

09:00 - 10:30 **■ New insights into the pathogenesis of systemic lupus erythematosus (SLE)** **Skalkotas Hall**
Chairs: Petros Sfikakis (Greece), Alexandre Belot (France) and Anna Glaser (United Kingdom)

09:00 **Innate immune DNA-sensing pathways in systemic lupus erythematosus (SLE)**
Vanja Sisirak (USA)

09:20 **Cell death in the pathogenesis of systemic lupus erythematosus (SLE)**
Michael Beresford (United Kingdom)

09:40 **CREM in immune regulation and autoimmunity**
Klaus Tenbrock (Germany)

10:00 **O12 - Interferon - plays a role in the pathogenesis of pediatric systemic lupus erythematosus and its activity correlates with disease activity**
Gian Marco Moneta (Italy)

10:10 **P124 - Emerging role for the renal glomerular endothelial cells as potent inflammatory contributors in juvenile-onset lupus nephritis**
Paraskevi Dimou (United Kingdom)

10:20 **P127 - The expression of IFN receptor chains on naïve and primed neutrophils**
Sophie Irwin (United Kingdom)

HPPR SESSION

09:00 - 10:30 **Workshop: Clinical rehabilitation skills in juvenile idiopathic arthritis (JIA)** **MC3.2 Room**
Functional impairment (musculoskeletal) and activity limitation
Facilitator: Sara Röstlund (Sweden)

ENCA SESSION

09:00 - 10:30 **ENCA programme** **MC2 Room**
 Please refer to page 45 for further details



10:30-11:00 Coffee break

PReS SESSIONS

11:00 - 12:30 ● **Scleroderma and related disorders** Banquet Hall

Chairs: Ivan Foeldvari (Germany), Ricardo Russo (Argentina) and Marija Perica (Croatia)

- 11:00 Raynaud phenomenon: clinical aspects and management of cases resistant to initial therapy
Clare Pain (United Kingdom)
- 11:20 What is new in juvenile scleroderma
Francesco Zulian (Italy)
- 11:40 Potential new therapeutic targets in scleroderma
Oliver Distler (Switzerland)
- 12:00 **O13** - Reliability and performance of the LoSCAT clinical score for the assessment of activity and tissue damage in a large cohort of patients with juvenile localized scleroderma
Anna Agazzi (Italy)
- 12:10 **O14** - Tocilizumab is a promising treatment option for therapy resistant juvenile localised scleroderma patients
Ivan Foeldvari (Germany)
- 12:20 **O14b** - New insights in cardiac involvement of juvenile systemic sclerosis patients: a 3D echocardiographic assessment unveils subclinical dysfunction of ventricles
Amra Adrovic (Turkey)

11:00 - 12:30 ■ **Pathogenesis of antiphospholipid syndrome in pediatric populations** Skalkotas Hall

Chairs: Tadej Avcin (Slovenia), Rolando Cimaz (Italy)

- 11:00 Pathogenic mechanisms of thrombotic and non-thrombotic manifestations in antiphospholipid syndrome (APS)
Pierluigi Meroni (Italy)
- 11:30 Effect of a PL in mouse fetal brain development
Guillermina Girardi (United Kingdom)
- 12:00 Long-term outcome of children born to mothers with antiphospholipid syndrome (APS)
Laura Andreoli (Italy)

HPPR SESSION

11:00 - 12:30 **Workshop: Medication and health counseling** MC3.2 Room

Health literacy (medication, nutrition, health behaviors)

Facilitator: Jan Jaap Van der Net (The Netherlands)

ENCA SESSION

11:00 - 12:30 **ENCA Programme** MC2 Room

Please refer to page 45 for further details

12:30-15:00 Lunch break

SPONSORED SYMPOSIA

13:00 - 14:00 **Satellite Symposium NOVARTIS** Banquet Hall

See detailed programme page 47

13:00 - 14:00 **Satellite Symposium ENZYVANT** Skalkotas Hall

See detailed programme page 47

ANNUAL GENERAL ASSEMBLY

14:00 - 15:00 PReS General Assembly

MC3.2 Room

POSTERS VIEWING

14:00 - 15:00 Poster viewing and poster guided tour

Poster area

Please refer to page 31 for further details

ENCA SESSION

14:00 - 15:00 ENCA programme

Please refer to page 45 for further details

PReS SESSIONS

15:00 - 17:00 ■ Pathogenesis of juvenile idiopathic arthritis (JIA)

Banquet Hall

Chairs: Lucy Wedderburn (United Kingdom), Johannes Roth (Germany) and Lovro Lamot (Croatia)

15:00 Dendritic cells and CD8(+) T cells in human autoimmune arthritis

Femke van Wijk (The Netherlands)

15:25 The role of S100 proteins in dendritic cell activation and tolerance

David Popp (Germany)

15:50 Tolerogenic dendritic cells as target to treat arthritis

John Isaacs (United Kingdom)

16:15 Biology of regulatory T cells in chronic arthritis

David Bending (United Kingdom)

16:40 **O15** - P75NTR/PRONGF up regulation in synovial tissues activates inflammatory responses in chronic arthritis patients

Gaetana Minnone (Italy)

16:50 **O15b** - A novel small molecule blocks IL-17-dependent, TCR-independent inflammatory pathway of synovitis in juvenile idiopathic arthritis

Abbe N Vallejo (USA)

15:00 - 17:00 PReS/HPPR joint session:

Skalkotas Hall

Exercise therapy, physical activity and sport in juvenile idiopathic arthritis (JIA)

Chairs: Janjaap van der Net (The Netherlands), Wineke Armbrust (The Netherlands)

15:00 Exercise and physical activity in healthy children - patterns and barriers

Joost Swart (The Netherlands)

15:35 Exercise and training in children with rheumatic diseases - development and challenges over the last decade

Otto Lelieveld (The Netherlands)

16:10 Specific sport habits in juvenile idiopathic arthritis (JIA) - patterns and barriers

Mette Nørgaard (Denmark)

ENCA SESSION

15:00 - 16:00 ENCA programme

Please refer to page 45 for further details

17:00 - 17:30 Coffee break



ORAL PRESENTATIONS

17:30 - 19:00	Oral presentations	Banquet Hall
	<i>Chairs: Silvia Magni-Manzoni (Italy), Yackov Berkun (Israel)</i>	
17:30	O16 - Three treatment strategies in recent onset DMARD naive juvenile idiopathic arthritis: first results of clinical outcome after 24 months <i>Petra Hissink Muller (The Netherlands)</i>	
17:40	O17 - Predictive value of magnetic resonance imaging in patients with juvenile idiopathic arthritis in clinical remission <i>Marta Mazzoni (Italy)</i>	
17:50	O18 - Baseline predictors of functional disability eight years after disease onset in the nordic juvenile idiopathic arthritis population-based cohort <i>Veronika Rypdal (Norway)</i>	
18:00	O19 - What is the outcome of juvenile idiopathic arthritis in adulthood? The monocentric experience of 414 patients followed in a transition tertiary clinic of rheumatology <i>Irene Pontikaki (Italy)</i>	
18:10	O20 - Identification of novel antibodies predictive of the development of uveitis in juvenile idiopathic arthritis (JIA) using high-density nucleic acid programmable protein arrays <i>David Gibson (United Kingdom)</i>	
18:20	O21 - New onset uveitis in patients with juvenile idiopathic arthritis under biological therapy <i>Irina Nikishina (Russia)</i>	
18:30	O22 - Microparticles as potential biomarkers of disease activity in anti-neutrophil cytoplasmic antibody - associated vasculitis <i>Milena Kostić (Serbia)</i>	
18:40	O23 - Plasmalemma vesicle-associated protein 1 (pv-1) as a marker of active disease in childhood vasculitis <i>Andrea Taddio (Italy)</i>	
18:50	O24 - Takayasu arteritis in childhood: retrospective experience from a tertiary referral center in South India <i>Sathish Kumar (India)</i>	

HPPR SESSION

17:30 - 19:00	Workshop: Teaching Clinical Skills	MC3.2 Room
	<i>Facilitators: Helen Foster (United Kingdom), Sharmila Jandial (United Kingdom) and Mercedes Chan (Canada)</i>	

POSTER GUIDED TOURS

Treatment of autoinflammatory diseases

Moderator: Natasa Toplak (Slovenia)

- P173** EVALUATION OF EFFICACY AND SAFETY OF OPOCALCIUM COLCHICINE, ANAKINRA AND CANAKINUMAB IN COLCHICINE-RESISTANT CHILDHOOD FAMILIAL MEDITERRANEAN FEVER / *K. Barut* - A. Adrovic - S. Sahin - A. Kaplan - O. Kasapcopur*
- P174** PROTON PUMP INHIBITORS TREATMENT IMPROVE THE DISEASE IN A NOVEL KNOCK-IN CAPS MODEL DEVELOPING SYSTEMIC AMYLOIDOSIS / *A. Bertoni* - S. Carta - E. Balza - F. Penco - S. Borghini - M. Fiore - C. Baldovini - P. Nozza - E. Ognio - F. Schena - P. Castellani - M. DiDuca - C. Pastorino - M. L. Trotta - I. Ceccherini - A. Martini - A. Rubartelli - M. Gattorno - S. Chiesa*
- P175** CANAKINUMAB DOSING IN PATIENTS WITH STILL'S DISEASE: EXPOSURE-RESPONSE ANALYSIS OF POOLED SJIA DATA BY AGE GROUPS / *E. Feist* - P. Quartier - B. Fautrel - R. Schneider - P. Sfriso - P. Efthimiou - L. Cantarini - K. Lheritier - K. Leon - C. S. Karyekar - A. Speziale*
- P176** IMPROVEMENT OF DISEASE ACTIVITY IN PATIENTS WITH COLCHICINE-RESISTANT FMF, HIDS/MKD AND TRAPS ASSESSED BY AUTOINFLAMMATORY DISEASE ACTIVITY INDEX (AIDAI): RESULTS FROM THE CLUSTER TRIAL / *I. Kone-Paut* - M. Hofer - S. Benseler - J. Kuemmerle-Deschner - A. Jansson - I. Rosner - A. Tommasini - S. Murias - O. Karadag - J. Levy - C. S. Karyekar - F. De Benedetti*

- P177** LONG-TERM EFFECTIVENESS OF CANAKINUMAB IN CHILDREN WITH FAMILIAL MEDITERRANEAN FEVER / *N. Gülez - B. Makay* - B. Sözeri*
- P178** EVALUATION OF A DOSING REGIMEN FOR TOCILIZUMAB IN PATIENTS YOUNGER THAN TWO YEARS OF AGE WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / *S. Wimalasundera* - N. L. Mallalieu - J. Hsu - K. Wang - C. Wells - I. Calvo Penades - R. Cuttica - H. I. Huppertz - R. Joos - Y. Kimura - D. Milojevic - M. Rosenkranz - K. Schikler - T. Constantin - C. Wouters*
- P179** JOINT INVOLVEMENT PREDICTS SEVERE PEDIATRIC CROHN'S DISEASE EVOLUTION / *N. Ouldali - J.-P. Hugot - J. Viala - M. Damir - C. Martinez-Vinson - U. Meinzer**
- P180** A DIAGNOSTIC SCORE FOR EARLY DETECTION OF MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS BASED ON AN IMPROPER LINEAR MODEL METHOD / *F. Minoia* - F. Bovis - S. Davi - A. Horne - M. Fischbach - M. Frosch - A. Huber - M. Jelusic-Drazic - S. Sawhney - D. McCurdy - C. A. Silva - D. Rigante - N. Ruperto - A. Martini - R. Q. Cron - A. Ravelli*
- P181** PREDICTORS OF INCOMPLETE RESPONSE TO TOCILIZUMAB THERAPY IN CHILDREN WITH SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS / *K. Nishimura* - S. Hattori - A. Oohara - T. Nozawa - R. Hara - S. Ito*
- P182** EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FMF: RESULTS FROM THE PHASE 3 CLUSTER TRIAL / *S. Ozen* - I. Kone-Paut - M. Hofer - J. van Der Hilst - A. Gül - P. Brogan - R. Manna - S. Murias - O. Karadag - S. Savic - Y. Gong - E. Vritzali - G. Junge - F. De Benedetti - E. Ben-Chetrit*
- P183** SEVERE ADVERSE EVENTS ASSOCIATED WITH USE OF BIOLOGIC THERAPY IN PATIENTS WITH SYSTEMIC JUVENILE ARTHRITIS: A SINGLE-CENTER STUDY / *R. A. Russo* - M. M. Katsicas*

Infections - Immunoregulation - Biomarkers

Moderator: Clio Mavragani (Greece)

- P216** THE FREQUENCY OF INFECTIONS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS ON BIOLOGIC AGENTS: ONE YEAR PROSPECTIVE STUDY / *D. Aygun - A. Adrovic* - S. Bektas - S. Sahin - K. Barut - H. Cokugras - Y. Camcioglu - O. Kasapcopur*
- P217** BIOMARKERS FOR THE DIAGNOSIS AND THE IDENTIFICATION OF RISK OF MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) / *C. Bracaglia* - D. Pires Marafon - I. Caiello - K. de Graaf - M. Ballabio - W. Ferlin - S. Davi' - G. Schulert - A. Ravelli - A. A. Grom - R. Nelson - C. de Min - F. De Benedetti*
- P218** ACTIVE TUBERCULOSIS IN CHILDREN AND ADOLESCENTS RECEIVING TUMOR NECROSIS FACTOR ALPHA INHIBITORS: A PTBNET CASE SERIES / *J. Calzada-Hernández* - M. Tebruegge - N. Ritz - E. Schölvinck - A. Noguera-Julian*
- P219** BIOCHEMICAL MARKERS OF CARDIOVASCULAR DISEASE IN CHILDREN WITH RHEUMATIC DISEASES / *I. Chyzheuskaya* - L. Byelyaeva - T. Yuraga*
- P220** FAECAL CALPROTECTIN AS SCREENING TOOL TO IDENTIFY INFLAMMATORY BOWEL DISEASE AMONG JUVENILE IDIOPATHIC PATIENTS: RESULTS FROM A MONOCENTRIC ITALIAN STUDY / *G. Ferrara* - L. Sancin - C. Bibalo - A. Tommasini - A. Taddio - S. Pastore*
- P221** AN IMMUNE-REGULATORY ROLE OF THE ALARMIN S100A8/A9 DURING COLLAGEN-INDUCED ARTHRITIS / *M. Kuhlencord* - S. Zenker - J. Roth - T. Vogl*
- P222** IN ACTIVE JUVENILE IDIOPATHIC ARTHRITIS THE HLA-DR ASSOCIATED NETWORK MODULE MAY DRIVES THE FUNCTIONALLY DICHOTOMIC PATHOGENIC IMMUNE SUBSETS FROM A COMMON PRECURSOR / *P. Kumar - J. Y. Leong - P. Chen - J. G. Yeo* - C. Chua - S. Saidin - S. Nur Hazirah - J. Tan - T. Arkachaisri - A. Consolaro - M. Gattorno - A. Martini - S. Albani*
- P223** IL-18 AS A DIAGNOSTIC BIOMARKER FOR SYSTEMIC JIA: DIFFERENTIATING SYSTEMIC JIA FROM CHILDHOOD LEUKAEMIA, NON-SYSTEMIC JIA SUBTYPES AND OTHER AUTO-IMMUNE CONDITIONS LIKE VASCULITIS / *A. Leek* - N. ter Haar - J. Wienke - A. el Idrissi - D. Holzinger - W. de Jager - S. Vastert*
- P224** A NOVEL IMMUNE-REGULATORY FUNCTION OF S100A8 IN DEVELOPING DENDRITIC CELLS / *D. Popp* - F. Rühle - W. de Jager - T. Vogl - J. Roth*
- P225** DIAGNOSTIC AND PROGNOSTIC VALUE OF SYNOVIAL FLUID IN PAEDIATRIC JUVENILE IDIOPATHIC ARTHRITIS / *S. Rasul* - A. Chieng - T. Freemont*

- P226** NEUTROPHILS PLAY A KEY ROLE IN THE INITIAL INFLAMMATORY CASCADE IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, DISPLAYING A SEPSIS-LIKE PHENOTYPE / *N. Ter Haar* - W. de Jager - R. Scholman - J. Meerding - M. Mokry - B. Vastert - S. de Roock*

Juvenile idiopathic arthritis - Outcome measures

Moderator: Alessandro Consolaro (Italy)

- P229** VALIDATING JADAS10 CUT-OFF VALUES FOR INACTIVE DISEASE, LOW DISEASE AND MODERATE DISEASE ACTIVITY LEVELS IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: A FINNISH MULTICENTRE STUDY / *M. Backström* - P. Tynjälä - H. Ylijoki - K. Aalto - A. Putto-Laurila - M.-M. Grönlund - J. Kärki - H. Pohjankoski - P. Keskitalo - S. Sard - M. Hietanen - S. Witter - H. Lehto - E. Löyttyniemi - P. Vähäsalo*
- P230** A LITERATURE REVIEW OF OUTCOME MEASURES USED IN JUVENILE IDIOPATHIC ARTHRITIS TRIALS- AS PART OF THE STEROID INDUCTION OF REMISSION IN JIA (SIRJIA) STUDY / *S. Deepak* - E. Baidam - F. McErlane on behalf of HTA 14/167/01 SIRJIA Trial Management Group*
- P231** SATISFACTION WITH CURRENT CONDITION IN JUVENILE IDIOPATHIC ARTHRITIS IS LINKED TO MORNING STIFFNESS BUT NOT TO BURDEN OF THERAPY / *E. Del Giudice* - P. van Dijkhuizen - S. de Roock - S. J. Vastert - S. F. Swart - N. M. Wulffraat*
- P232** BURDEN OF DISEASE, THERAPY AND PHENOTYPES OF JUVENILE PSORIATIC ARTHRITIS – DATA FROM THE NATIONAL PAEDIATRIC RHEUMATOLOGIC DATABASE (NPRD) OVER A 15-YEAR PERIOD / *N. Derksen - M. Niewerth - C. Sengler - N. Geisemeyer - R. M. Küster - I. Foeldvari - J.-P. Haas* - K. Minden*
- P233** VALIDATION OF BIOMARKERS TO PREDICT FLARE IN POLYARTICULAR JIA UPON STOPPING ANTI-TNF THERAPY / *D. Lovell* - S. Ringold - S. Eastman*
- P234** ANALYSIS OF RISK FACTORS OF OCULAR COMPLICATIONS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS / *V. Muratore* - S. Calandra - V. Ravaschio - G. Giancane - A. Alongi - A. Pistorio - A. Consolaro - B. Schiappapietra - A. Ravelli*
- P235** DISCORDANCE BETWEEN CHILD/PARENT ASSESSMENT OF WELL-BEING AND PAIN AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN A MULTINATIONAL COHORT OF 9137 CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *E. B. Nordal* - A. Consolaro - R. Cimaz - R. Cuttica - F. De Benedetti - Y. El Miedany - T. Herlin - M. M. Katsicas - P. Quartier - G. Susic - S. Vilaiyuk - N. Wulffraat - A. Martini - N. Ruperto - A. Ravelli on behalf of the EPOCA study group*
- P236** OROFACIAL SYMPTOMS AND ORAL HEALTH-RELATED QUALITY OF LIFE IN JIA: A TWO-YEAR OBSERVATIONAL FOLLOW-UP STUDY / *H. Rahimi* - M. Twilt - L. Spiegel - T. Herlin - B. Koos - A. Küseler - T. K. Pedersen - P. Stoustrup*
- P237** CAN WE PREDICT CLINICALLY INACTIVE DISEASE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS? / *S. J. W. Shoop-Worrall* - S. M. Verstappen - J. E. McDonagh - W. Thomson - K. L. Hyrich on behalf of CAPS*
- P238** CHARACTERISTICS AND SAFETY OUTCOMES OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN TWO US HEALTHCARE CLAIMS DATABASES / *T. A. Simon* - S. Singhal - N. Ray - Z. Guo*
- P239** PREDICTION OF INACTIVE DISEASE IN A MULTICENTRE INCEPTION COHORT OF JIA PATIENTS / *P. Van Dijkhuizen - O. Aidonopoulos - N. ter Haar - D. Pires Marafon - S. Magni-Manzoni - Y. E. Ioannidis - L. Putignani - S. J. Vastert* - C. Malattia - F. De Benedetti - A. Martini*

Juvenile idiopathic arthritis treatment

Moderator: Traudel Saurenmann (Switzerland)

- P240** METHOTREXATE AS FIRST LINE THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS: MYTH OR REALITY? / *J. Agnolucci* - M. E. Zannin - F. Vittadello - G. Martini - A. Meneghel - F. Zulian*
- P241** METHOTREXATE USE AND ROUTE OF ADMINISTRATION IN JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE CHILDHOOD ARTHRITIS AND RHEUMATOLOGY RESEARCH ALLIANCE (CARRA) REGISTRY / *S. Ringold - F. Xie - D. Horton - M. Mannion - T. Beukelman* on behalf of CARRA Registry Investigators*
- P242** IDENTIFICATION OF OPTIMAL SUBCUTANEOUS DOSES OF TOCILIZUMAB IN CHILDREN WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS / *F. De Benedetti* - H. Brunner - N. Ruperto - A. V. Ramanan - R. Cuttica - J. E. Weiss - M. L. Henrickson - N. Rubio - C. A. Silva - R. Merino Munoz - M. L. Gamir Gamir - J. Hsu - K. Bharucha - R. Upmanyu - S. Wimalasundera - A. Kadva - N. L. Mallalieu - A. Martini - D. Lovell*

- P243** THE NATIONAL CENTRE FOR PAEDIATRIC RHEUMATOLOGY (NCPR) EXPERIENCE OF THE USE OF TOCILIZUMAB (RO-ACTEMRA) IN THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA): A 7-YEAR STORY / *C. Foley* - W. Madan - E.-J. MacDermott - O. G. Killeen*
- P244** MODULATING TREG FUNCTION WITH NICOTINAMIDE (VIT B3) IN JIA / *L. Nijhuis* - J. Peeters - A. Lalmohamed - J. Van Loosdregt - B. Vastert*
- P245** THE ANALYSIS OF A NEUTROPENIA CASES IN JUVENILE IDIOPATHIC ARTHRITIS UNDER TOCILIZUMAB THERAPY / *M. Kaleda - I. Nikishina* - O. Kostareva*
- P246** SUBCUTANEOUS ABATACEPT IN PATIENTS AGED 6-17 YEARS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 2-YEAR EFFICACY AND SAFETY RESULTS / *N. Ruperto* - H. I. Brunner - N. Tzaribachev - I. Louw - A. Berman - I. Calvo - R. Cuttica - G. Horneff - M. Henrickson - D. J. Kingsbury - I. Foeldvari - M. E. Paz Gastanaga - B. Lauwerys - K. Minden - J. Bohnsack - J. C. Breedt - R. van Zyl - X. Li - M. Nys - R. Wong - S. Banerjee - A. Martini - D. J. Lovell on behalf of Paediatric Rheumatology International Trials Organization (PRINTO) / *Pediatric Rheumatology Collaborative Study Group (PRCSG)**
- P247** COMPARATIVE ASSESSMENT OF GROWTH IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH BIOLOGICAL THERAPY WITH A DIFFERENT MECHANISM OF ACTION (TOCILIZUMAB, ETANERCEPT, ADALIMUMAB, ABATACEPT) / *V. Seraya* - E. Zholobova - A. Vitebskaya*
- P248** FAMILIES' VIEWS ON THE FEASIBILITY OF A CORTICOSTEROID TRIAL IN JIA: A QUALITATIVE STUDY / *F. C. Sherratt* - L. Roper - E. Baildam - M. W. Beresford - S. R. Stones - A. Ramanan - H. Foster - F. McErlane - M. Rooney - M. Peak - B. Young*
- P249** PATTERNS AND SWITCHING OF FIRST-LINE BIOLOGICS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN TWO US HEALTHCARE CLAIMS DATABASES / *T. A. Simon* - S. Singhal - N. Ray - Z. Guo*
- P250** AN INTERNET-BASED SELF-MANAGEMENT PROGRAM FOR ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA): A RANDOMIZED CONTROLLED TRIAL (RCT) / *L. R. Spiegel* - J. Stinson - S. Campillo - T. Cellucci - P. Dancy - C. Duffy - J. Ellsworth - B. Feldman - A. Huber - N. Johnson - P. McGrath - A. Rosenberg - N. Shiff - S. Tse - L. Tucker - C. Victor - S. Luca*
- P251** 3 YEAR FOLLOW-UP OF ACUTE-JIA* COHORT *AGGRESSIVE COMBINATION DRUG THERAPY IN VERY EARLY POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS / *P. Tynjälä - M. Tarkiainen* - P. Vähäsalo - L. Kröger - K. Aalto - K. Rebane - M. Malin - K. Markula-Patjas - E. Piippo-Savolainen - P. Lahdenne*
- P252** ORAL OR SUBCUTANEOUS METHOTREXATE: COMPARISON OF THE EFFICACY IN INDUCING SUSTAINED DISEASE REMISSION IN CHILDREN WITH OLIGOARTICULAR JIA / *C. Trincianti* - M. F. Gicchino - E. H. P. van Dijkhuizen - B. Schiappapietra - E. Zaccheddu - G. Giancane - G. Bracciolini - D. P. Marafon - S. Magni-Manzoni - L. Villa - C. Gandolfo - F. De Benedetti - N. Ruperto - A. Ravelli - A. Consolaro*

Juvenile dermatomyositis - Scleroderma

Moderator: Helga Sanner (Norway)

- P274** THE RELATIONSHIP BETWEEN HAND GRIP STRENGTH, PAIN LEVEL AND HAND FUNCTIONALITY IN CHILDREN WITH JUVENILE SCLERODERMA / *A. Dag* - E. Tarakci - A. Adrovic - O. Kasapcopur*
- P275** LONG TERM OUTCOME OF JUVENILE LOCALIZED SCLERODERMA: DATA FROM A SINGLE PEDIATRIC RHEUMATOLOGY CENTER / *G. Fadanelli - A. Agazzi - F. Vittadello - F. Zulian - G. Martini**
- P276** UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT PROJECT. CHARACTERISTICS OF THE FIRST 97 PATIENTS AT FIRST ASSESSMENT. WWW.JUVENILE-SCLERODERMA.COM / *I. Foeldvari* - J. Klotsche - O. Kasapcopur - A. Adrovic - V. Stanevicha - K. Torok - T. Terreri - E. Alexeeva - M. Katsikas - V. Smith - F. Sztajn bok - T. Avcin - R. Cimaz - J. Anton - M. Kostik - T. Lehman - W.-A. Sifuentes-Giraldo - S. Appenzeller - M. Janarthanan - M. Moll - D. Nemcova - M. J. Santos - C. Battagliotti - L. Berntson - J. Brunner - D. Eleftheriou - L. Harel - T. Kallinich - K. Minden - S. Nielsen - Y. Uziel - A. Stevens - C. Pilkington - N. Helmus*
- P277** SYSTEMIC CAPILLARY LEAK SYNDROME IN JUVENILE DERMATOMYOSITIS / *A. Meneghel* - G. Martini - C. Birolo - A. Tosoni - A. Pettenazzo - F. Zulian*
- P278** CLINICAL AND LABORATORY ASSESSMENT OF 87 PATIENTS WITH JUVENILE DERMATOMYOSITIS / *J. M. Mosquera Angarita* - E. Quesada - D. Clemente - A. Boteanu - J. C. Nieto - L. Riancho-Zarrabeitia - J. Sánchez-Manubens - E. Nuñez - M. J. Lirola - S. Copete - M. Camacho-Lovillo - M. Martínez-Morillo - P. Alcañiz - M. Medrano - M. A. Carballo - J. Antón - E. Iglesias*

- P279** EXPRESSION OF TYPE I AND TYPE II INTERFERONS IS INCREASED IN MUSCLE BIOPSIES OF JUVENILE DERMATOMYOSITIS PATIENTS AND RELATED TO CLINICAL AND HISTOLOGICAL FEATURES / *R. Nicolai - G. M. Moneta* - S. Rosina - C. Fiorillo - D. Pires Marafon - M. Verardo - L. Bracci-Laudiero - C. Minetti - A. Ravelli - F. De Benedetti*
- P280** GROWTH AND PUBERTY IN JUVENILE DERMATOMYOSITIS, A LONGITUDINAL MULTICENTER PRINTO STUDY / *E. Nordal* - A. Pistorio - M. Rygg - G. Giancane - M. Hofer - J. A. Melo-Gomes - B. Bica - X. Norambuena - V. Stanevicha - R. Ten Cate - O. Vougiouka - J. Brunner - G. Dannecker - P. Pratsidou-Gertsis - G. Simonini - H. Venning - S. Pastore - A. Ravelli - A. Martini - N. Ruperto on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO)*
- P281** QUALITY OF LIFE EVALUATION IN NEW ONSET JUVENILE DERMATOMYOSITIS PATIENTS FROM THE PRINTO TRIAL / *A. Guariento - E. Fueri - G. Giancane - F. Zulian - A. Ravelli - B. Magnusson - T. Avcin - F. Corona - V. Gerloni - C. Bracaglia - R. Cimaz - A. Meini - S. Martino - A. Pagnier - M. Rodiere - C. Soler - V. Stanevicha - R. Ten Cate - Y. Uziel - J. Vojinovic - S. Angioloni - L. Villa - M. Pesce - I. Gregorini - C. Pallotti - A. Martini - A. Pistorio - N. Ruperto**
- P282** COMPARISON OF TREATMENT APPROACH, SIDE EFFECTS AND CUMULATIVE DAMAGE OF CHILDREN WITH JUVENILE DERMATOMYOSITIS FOLLOWED IN TWO EUROPEAN TERTIARY CARE REFERRAL CENTERS / *G. C. Varnier* - A. Consolaro - C. Pilkington - S. Maillard - S. Zaffarano - A. Martini - A. Ravelli on behalf of Juvenile Dermatomyositis Research Group, JDRG, London, UK*
- P283** CONE BEAM COMPUTED TOMOGRAPHY FOR THE ASSESSMENT OF LINEAR SCLERODERMA OF THE FACE / *C. Di Giovanni - S. Puggina - A. Meneghel - S. Trainito - G. Martini - F. Zulian**

POSTER VIEWING

Autoinflammatory diseases

- P184** DIFFERENTIAL DIAGNOSIS OF NON-BACTERIAL AND ACUTE HEMOTOGENOUS OSTEOMYELITIS / *O. Kopchak* - M. Kostik*
- P185** NEW PATHOGENIC FAMILIAR HETEROZYGOUS NLRP3 GENE MISSENSE VARIANT ASSOCIATED WITH RECCURENT PERICARDITIS CLINICAL PRESENTATION / *D. S. Lazarevic* - J. Vojinovic*
- P186** A COHORT OF PATIENTS WITH AUTOINFLAMMATORY DISEASES FOLLOWED-UP IN A UNIT OF PAEDIATRIC AND TRANSITIONAL RHEUMATOLOGY: A DESCRIPTIVE STUDY / *M. Llop Vilatella* - A. Boteanu - M. A. Blazquez Cañamero - W. A. Sifuentes Giraldo - M. L. Gamir Gamir*
- P187** GENETIC AND CLINICAL PROFILE OF A PAEDIATRIC POPULATION WITH FMF IN SICILY / *M. C. Maggio* - C. Fabiano - R. Scondotto - G. Vitaliti - G. Corsello*
- P188** ANTI-IL1 IN PATIENTS WITH LOW PENETRANCE MUTATIONS FOR AUTOINFLAMMATORY DISEASES: TUSCANY AND SICILIAN CASE SERIES FROM PAEDIATRIC TO ADULT AGE / *M. C. Maggio* - L. Cantarini - G. Corsello - U. Corpora - R. Cimaz*
- P189** GENETIC AND CLINICAL PROFILE OF A SICILIAN POPULATION WITH R92Q MUTATION / *M. C. Maggio* - C. Fabiano - G. Vitaliti - G. Corsello*
- P190** A PAEDIATRIC FMF PATIENT WITH RECURRENT PRIAPISM DURING ATTACKS / *B. Makay* - N. Gülez*
- P191** SEVERE ARTHRITIS AS CLINICAL PRESENTATION IN A A NOVEL CASE OF COPA SYNDROME / *S. Volpi - M. Mariani* - C. Pastorino - A. K. Shum - A. Ravelli - M. Gattorno - P. Picco*
- P192** PAEDIATRIC AUTOINFLAMMATORY DISEASES IN CYPRUS: INSIGHTS FROM THE NATIONAL REGISTRY / *D. Maritsi* - A. Elia - M. Kolliou - M. Kousparou - M. Onoufriou*
- P193** ANTIPHOSPHOLIPID SYNDROME AS A DIAGNOSTIC AND THERAPEUTIC PROBLEM / *A. Sobiesiak - A. Rybkowska - M. Tomaszek - V. Opoka-Winiarska**
- P194** ANHIDROTIC ECTODERMAL DYSPLASIA WITH AUTOINFLAMMATORY MANIFESTATIONS / *F. Orlando* - E. Bruzzese - M. I. Spagnuolo - A. Guarino - M. Alessio*
- P195** THE PHENOTYPIC ROLE OF HETEROZYGOUS MUTATIONS IN FAMILIAL MEDITERRANEAN FEVER / *S. ahin - Z. B. Özçakar* - N. Cakar - S. Ozdel - F. Yalcinkaya*
- P196** EVALUATION OF HIGH MOBILITY GROUP BOX 1 PROTEIN AS AN INFLAMMATION MARKER IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / *B. Öztürk* - E. Baskın - K. Gülleroğlu - N. Bayraktar - F. Şahin*

- P197** BRITISH PAEDIATRIC SURVEILLANCE UNIT (BPSU) STUDY OF BEHCET'S SYNDROME IN CHILDREN & YOUNG PEOPLE IN THE UNITED KINGDOM / *C. E. Pain* - E. Latham - M. W. Beresford - P. Brogan - F. Fortune - R. J. Moots - R. Murphy*
- P198** INVESTIGATING THE CLINICAL AND GENETIC PROFIL IN A COHORT OF PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / *E. Papadopoulou-Alataki* - O. Vamperzi - C. Trakatelli - S. Katafigiotis - V. Galanopoulou - A. Alataki - A. Lambropoulos*
- P199** CXCL10 AND CXCL9 GENETIC VARIANTS IN PEDIATRIC PATIENTS WITH PERIODIC FEVER SYNDROME WITH APHTHOUS STOMATITIS, PHARYNGITIS, AND ADENITIS (PFAPA) / *D. Perko* - M. Debeljak - N. Toplak - T. Avčin*
- P200** CLINICAL AND HISTOLOGICAL PRESENTATION OF THE INITIAL SKIN INVOLVEMENT IN BLAU SYNDROME / *J. Poline* - O. Fogel - C. Miceli-Richard - C. Wouters - M. D. Vignon-Pennamen - E. Hachulla - U. Meinzer - E. Bourrat*
- P201** SUCCESSFUL USE OF TOFACITINIB IN A 6-YEAR-OLD PATIENT WITH SAVI SYNDROME. / *S. Rodionovskaya* - S. Zaytseva - S. Salugina - E. Fedorov - I. Tsymbal*
- P202** MONOGENIC AUTOINFLAMMATORY DISEASES IN THE PRACTICE OF A RHEUMATOLOGIST IN RUSSIA / *S. O. Salugina* - E. S. Fedorov - N. N. Kuzmina - E. A. Kamenets - E. U. Zaharova*
- P203** CHARACTERISTIC OF THE FAMILIAL MEDITERRANEAN FEVER PATIENTS PRESENTED WITH MUSCULOSKELETAL FINDINGS / *B. Sozeri* - D. Kurtulus - T. Demircan Bilen - G. Senay Karagoz - I. Islek*
- P204** CHILDREN WITH AUTOINFLAMMATORY DISEASES IN BRITISH COLUMBIA: YEARS OF DELAY BEFORE DIAGNOSIS / *L. Tucker* - J. Tekano - D. Cabral - J. Guzman - K. Morishita - K. Houghton - K. Brown*

Disease outcome

- P205** DISORDERS OF RESPIRATORY ORGANS IN CHILDREN WITH RHEUMATIC DISEASES / *O. A. Oshlyanska**
- P206** FEATURES OF THE LIVER FUNCTIONAL STATUS IN CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS / *N. S. Shevchenko* - L. F. Bogmat - I. N. Bessonova*
- P207** INVESTIGATION OF THE FUNCTION OF EXTERNAL RESPIRATION IN CHILDREN WITH RHEUMATIC DISEASES / *N. S. Shevchenko* - L. F. Bogmat - M. V. Demjanenko - I. D. Savvo*
- P208** CHANGES OF THE CARDIOVASCULAR SYSTEM IN THE STRUCTURE OF THE COMORBIDITY IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC DISEASES / *L. F. Bogmat - N. S. Shevchenko* - I. N. Bessonova - V. V. Nikonova - M. V. Demyanenko*
- P209** GLOBALISATION OF PAEDIATRIC MUSCULOSKELETAL MATTERS' (PMM) / *N. Smith* - S. Jandial - R. Wyllie - C. English - B. Davies - R. Khubchandani - M. Chan - J. Munro - V. Ferriani - C. Saad Magalhães - R. Russo - J. Yan - C. Scott - S. Charuvanij - K. Khawaja - J. Vojinovic - T. Rapley - H. Foster*
- P210** PAEDIATRIC MUSCULOSKELETAL (MSK) TRIAGE IN THE COMMUNITY – RIGHTPATH – A PILOT STUDY / *N. Smith* - S. Jandial - J. Firth - H. Light - K. Kinsey - N. Snowden - J. McNaught - T. Rapley - A. Nye - H. Foster*
- P211** HAND GRIP STRENGTH, PINCH GRIP STRENGTHS AND MANUAL DEXTERITY IN CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / *E. Tarakci* - N. Arman - S. Sahin - A. Adrovic - K. Barut - O. Kasapcopur*

Imaging

- P212** INTRA AND INTER OBSERVER RELIABILITY OF ULTRASOUND FOR THE JOINTS EVALUATION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: THE JIRECHO STUDY / *L. Rossi-Semerano* - A. Saraux - A. Von Scheven - S. Breton - M. Bossert - S. Boiu - E. Chatelus - G. Durand - P. Dusser - S. Jean - L. Goumy - A. Mathiot - S. Chapelière - G. Mouterde - F. Nugues - A. Ould Hennia - B. Rey - C. Salliot - L. Sparsa - F. Hofer - S. Jousse-Joulin*
- P213** MUSCULOSKELETAL ULTRASONOGRAPHIC AND MAGNETIC RESONANCE IMAGING FINDINGS IN JUVENILE SCLERODERMA / *M. Tsinti* - V. Dermentzoglou - E. Tsitsami*

Immunodeficiency and infection related arthritis

- P214** COMMUNE VARIABLE IMMUNODEFICIENCY MIMICKING SARCOIDOSIS IN PEDIATRIC AGE: A CASE REPORT / *E. Marrani* - I. Maccora - T. Giani - R. Cimaz - G. Simonini*
- P215** REACTIVE ARTHRITIS TRIGGERED BY YERSINIA – THE ANALYSIS OF 20 CASES / *J. Postępski - A. Rybkowska - V. Opoka-Winiarska* - A. Sobiesiak - E. Olesińska*

Immunoregulation and basic science

- P228** TOLL-LIKE RECEPTOR 2 (TLR2) ARG753GLN AND TOLL-LIKE RECEPTOR 4 (TLR4) THR399ILE POLYMORPHISMS IN CHILDREN WITH RHEUMATIC FEVER IN LATVIA / *M. Visnevska* - V. Stanevica - V. Rovite - Z. Davidsonsone - A. Scegolevs - R. Santare*

Juvenile idiopathic arthritis (oligo, poly, psoriatic)

- P253** HOW DO PAEDIATRIC PAIN EXPERTS AND HEALTHCARE PROFESSIONALS PRIORITISE PATIENT-REPORTED PAIN INFORMATION FROM CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS? / *R. R. Lee* - A. Rashid - G. Daniela - W. Thomson - L. Cordingley*
- P254** PAIN AND THE EFFECT ON EVERY DAY LIFE IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *B. Mahler* - S. Esbersen - T. Herlin*
- P255** PRESCRIBING PATTERNS IN JUVENILE IDIOPATHIC ARTHRITIS: A SURVEY OF CURRENT PRACTICE IN THE UNITED KINGDOM / *D. Hawley - H. E. Foster - M. W. Beresford - A. Ramanan - T. Rapley - F. McErlane**
- P256** THE USABILITY OF CELL PHONE BASED AUTOMATED MONITORING OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / *K. Mikola* - K. Aalto - P. Lahdenne - H. Kautiainen*
- P257** ADIPOKINES IN JUVENILE IDIOPATHIC ARTHRITIS, ARE THEY USEFUL AS INFLAMMATORY ACTIVITY MARKERS? / *E. Nuñez-Cuadros - R. Galindo Zavala* - G. Díaz-Cordovés Rego - L. Artacho González - A. L. Urda Cardona*
- P258** A POPULATION BASED STUDY ON SCREENING FOR CELIAC DISEASE AND LEVELS OF CELIAC-RELATED ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA) / *A. Öman* - T. Hansson - M. Carlsson - L. Berntson*
- P259** EARLY ONSET ANA-POSITIVE JIA IN THE SWEDISH PAEDIATRIC RHEUMATOLOGY REGISTRY / *B. Magnusson - S. Omarsdottir* - E. Hagel on behalf of Board of the Registry*
- P260** ASSOCIATED AUTOIMMUNE DISEASES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *A. Omerčahić Dizdarević* - V. Selmanović - A. Čengić - S. Šabanović - M. Mujić*
- P261** LONG-TERM IMPACT OF JUVENILE IDIOPATHIC ARTHRITIS ON QUALITY OF LIFE OF ADULT PATIENTS IN GREECE / *G. C. Paskalis* - D. Dimopoulou - M. Trachana - P. Pratsidou-Gertsi - M. Stavrakidou - T. Oikonomou - T. Dimitroulas - A. Garyfallos*
- P262** PATIENTS' REPORTED IMPACT OF TEMPOROMANDIBULAR JOINT (TMJ) INVOLVEMENT IN JUVENILE IDIOPATHIC ARTHRITIS (JIA): DEVELOPMENT OF A JUVENILE ARTHRITIS TMJ SELF-REPORTED ASSESSMENT (JATA) QUESTIONNAIRE / *D. Pires Marafon - A. Arduini - L. Tanturi de Horatio - D. Barbuti - R. Nicolai - F. De Benedetti - S. Magni Manzoni**
- P263** SHARE LATIN AMERICA – FIRST STEPS / *I. H. Rotstein Grein* - C. S. Magalhães - B. G. Martin - A. Strickler - X. Norambuena - C. Navarrete - Y. Gavidia - M. Alegria - M. M. Katsicas - R. Russo - A. C. L. Held - L. C. Coelho - I. Ferreira - H. B. Gomes - N. Ruperto - N. Wulffraat*
- P264** SHARE LATIN AMERICA – BRAZILIANS'S FAMILIES VIEW ON STANDARD OF CARE FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / *I. H. Rotstein Grein* - M. Bandeira - C. S. Magalhães - L. G. Portasio - C. A. Len - M. T. R. A. Terreri - S. K. F. D. Oliveira - L. B. P. Marques - G. Pillegi - S. Appenzeller - F. R. Sztajn bok - T. C. M. V. Robazzi - A. J. P. D. Moraes - M. M. Fraga - A. Islabão - N. Wulffraat*
- P265** SAFETY OF ADALIMUMAB ± METHOTREXATE FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): STRIVE REGISTRY / *N. Ruperto* - H. Brunner - K. Nanda - M. Toth - I. Foeldvari - J. Bohnsack - D. Milojevic - C. Rabinovich - D. Kingsbury - K. Marzan - P. Quartier - K. Minden - E. Chalom - G. Horneff - R. Kuester - J. Dare - M. Bereswill - J. Kalabic - H. Kupper - A. Martini - D. Lovell*
- P266** ANTI-CITRULLINATED PROTEIN/PEPTIDE ANTIBODIES (ACPA) IN JUVENILE IDIOPATHIC ARTHRITIS - A SWEDISH COHORT / *R. Saleh* - E. Sundberg - M. Hansson - B. Magnusson - L. Padyukov - H. Erlandsson Harris*
- P267** INCIDENCE OF JUVENILE IDIOPATHIC ARTHRITIS IN FINLAND, 2000-2013. / *S. Sard* - T. Pokka - P. Vähäsalo*
- P268** DEVELOPING, EVALUATING AND IMPLEMENTING SMARTPHONE APPLICATIONS FOR YOUNG PEOPLE LIVING WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A SCOPING REVIEW OF EMPIRICAL RESEARCH / *S. R. Stones**

- P269** T CELL RESPONSE AFTER VARICELLA VACCINATION IN CHILDREN WITH JIA TREATED WITH BIOLOGIC THERAPY / *N. Toplak** - *A. N. Kopitar* - *A. Ihan* - *T. Avcin*
- P270** 2D SHEAR WAVE ELASTOGRAPHY TO REVEAL METHOTREXATE-INDUCED HEPATIC FIBROSIS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / *M. Tsinti** - *V. Dermentzoglou* - *E. Tsitsami*
- P271** EFFICACY AND TOLERABILITY OF SWITCHING FROM SUBCUTANEOUS TO ORAL ROUTE OF METHOTREXATE ADMINISTRATION IN JUVENILE IDIOPATHIC ARTHRITIS / *M. Tsinti** - *V. Dermentzoglou* - *E. Tsitsami*
- P272** MANY PEDIATRIC PSORIATIC ARTHRITIS PATIENTS ARE ASSOCIATED WITH FIBROMYALGIA SYNDROME COMPARED TO OTHER SUBTYPES OF JIA. / *K.-I. Yamaguchi** - *T. Tsuda* - *M. Kishimoto* - *M. Okada*

Juvenile dermatomyositis

- P284** CORRELATIONS BETWEEN CLINICAL AND OBJECTIVE MUSCLE SCORES IN JUVENILE DERMATOMYOSITIS ASSESSED AFTER LONG-TERM FOLLOW-UP / *K. S. Berntsen** - *T. Raastad* - *B. Flatøe* - *I. Sjaastad* - *H. Sanner*
- P285** ABDOMINAL MANIFESTATIONS IN JUVENILE DERMATOMYOSITIS / *C. M. Besnard** - *M. Guarella* - *N. Fabien* - *P. Quartier* - *L. Musset* - *N. Bardin* - *M. Desjonquères* - *B. Chabrol* - *A.-L. Jurquet* - *K. Retornaz* - *A. Belot* - *B. Bader-Meunier*
- P286** MUSCULAR WEAKNESS IN CHILDREN WITH JUVENILE DERMATOMYOSITIS INDUCES GAIT DEVIATIONS WITH PROPULSION REDUCTION IN LEVEL WALKING / *M. Hartmann* - *J. Merker* - *K. Koestner* - *B. Huegle* - *R. Haefner* - *A. Schwirtz* - *J.-P. Haas**
- P287** DEVELOPMENT OF CONSENSUS-BASED TREAT-TO-TARGET PROTOCOLS FOR THE MANAGEMENT OF JUVENILE DERMATOMYOSITIS IN GERMANY / *C. Hinze** - *P. Oommen* - *F. Dressler* - *U. Schara* - *F. Weller-Heinemann* - *J. Brunner* - *D. Föll* - *E. Lainka* - *U. Neudorf* - *T. Schwarz* - *F. Speth* - *A. Urban* - *W. Müller-Felber* - *J.-P. Haas* on behalf of Working Group Juvenile Dermatomyositis of the German Society for Pediatric Rheumatology's PROKIND Initiative
- P288** ANTI-KU ANTIBODIES IN TWO PAEDIATRIC CASES WITH JUVENILE DERMATOMYOSITIS-SCLERODERMA OVERLAP AND LITERATURE REVIEW: WHY IS IT IMPORTANT TO KNOW? / *P. Khaosut** - *S. Castagno* - *A. Aluko* - *M. Al-Obaidi*
- P289** CAPILLARY MICROSCOPY IN JUVENILE DERMATOMYOSITIS IS NOT STRONGLY CORRELATED TO CLINICAL AND LABORATORY MARKERS OF DISEASE ACTIVITY / *J.-P. Haas** - *K. Köstner* - *B. Hügler* - *F. Speth*
- P290** A PROFILE OF MYOSITIS AUTOANTIBODIES IN AN IRISH COHORT OF JUVENILE DERMATOMYOSITIS (JDM) / MYOSITIS PATIENTS. / *J. M. Macmahon** - *V. Tormey* - *E. J. MacDermott* - *O. Killeen*
- P291** CLINICAL CHARACTERISTICS OF CHILDREN AND ADOLESCENTS FROM THE BRAZILIAN REGISTRY OF MYOSITIS: AN INCEPTION COHORT STUDY / *C. S. Magalhaes** - *A. Sallum* - *T. Robazzi* - *A. J. Moraes* - *S. Oliveira* - *F. Sztajnbok* - *L. Carvalho* - *L. Marques* - *M. T. Terreri* - *S. Sacchetti* - *S. Appenzeller* - *A. P. Vecchi* - *A. Cavalcante* - *M. Bandeira* - *C. Len* - *C. Silva*
- P292** THE CASE OF FATAL LUNG INJURY IN JUVENILE DERMATOMYOSITIS / *L. I. Omelchenko* - *O. A. Oshlyanska** - *V. G. Ivanova*
- P293** ANTI- MELANOMA DIFFERENTIATION ASSOCIATED GENE 5(MDA5) AUTOANTIBODY AND INTERFERONS IN JUVENILE DERMATOMYOSITIS COMPLICATED WITH RAPID PROGRESSIVE- INTERSTITIAL LUNG DISEASE / *K. Yamazaki**

Macrophage activation syndrome

- P294** TRANSFUSION-RELATED ACUTE LUNG INJURY FOLLOWING PLATELET TRANSFUSION IN A CHILD WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS COMPLICATED BY MACROPHAGE ACTIVATION SYNDROME / *A. Gagro** - *A. M. Pasini* - *I. Skaric*
- P295** NEXT GENERATION SEQUENCING ANALYSIS OF FAMILIAL HAEMOPHAGOCYtic LYMPHOHISTIOCYTOSIS (HLH) RELATED GENES IN MACROPHAGE ACTIVATION SYNDROME AND SECONDARY HLH / *C. Passarelli** - *M. Pardeo* - *I. Caiello* - *E. Pisaneschi* - *A. Novelli* - *F. De Benedetti* - *C. Bracaglia*
- P296** IFNG AND IFNG INDUCIBLE GENES ARE STRONGLY UP-REGULATED IN THE LIVER FROM A PATIENTS WITH ACTIVE SECONDARY HEMOPHAGOCYtic LYMPHOHISTIOCYTOSIS (HLH) / *G. Prencipe** - *I. Caiello* - *M. Pardeo* - *A. Insalaco* - *G. Marucci* - *F. De Benedetti* - *C. Bracaglia*

Scleroderma and related syndromes

- P297** CLINICAL CASE: CONGENITAL SYSTEMIC SCLERODERMA / *M. Bulegenova** - *G. Erdjanova* - *A. Aytbaykyzy*
- P298** JUVENILE SCLERODERMA: EPIDEMIOLOGY, CLINICAL AND IMMUNOLOGY FEATURES IN MEXICAN CHILDREN. / *L. Aparicio* - *M. T. Braña* - *S. Osorio* - *Y. Ramirez* - *A. Rodríguez* - *E. Faugier* - *R. Maldonado* - *T. Diaz**
- P299** IS THERE A DIFFERENCE IN THE PRESENTATION OF MALE AND FEMALE PATIENTS WITH DIFFUSE SUBTYPE OF JUVENILE SYSTEMIC SCLEROSIS? RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT WWW.JUVENILE-SCLERODERMA.COM / *I. Foeldvari** - *J. Klotsche* - *O. Kasapcopur* - *A. Adrovic* - *V. Stanevicha* - *T. Terreri* - *E. Alexeeva* - *M. Katsikas* - *V. Smith* - *J. Anton* - *R. Cimaz* - *M. Kostik* - *T. Lehman* - *W.-A. Sifuentes-Giraldo* - *F. Sztajn bok* - *T. Avcin* - *M. Janarthanan* - *M. J. Santos* - *M. Moll* - *D. Nemcova* - *C. Battagliotti* - *J. Brunner* - *D. Eleftheriou* - *L. Harel* - *T. Kallinich* - *K. Minden* - *S. Nielsen* - *K. Torok* - *Y. Uziel* - *A. Stevens* - *C. Pilkington* - *N. Helmus*
- P300** IS THERE A DIFFERENCE IN THE CLINICAL PRESENTATION OF JUVENILE SYSTEMIC SCLERODERMA PATIENTS ACCORDING THE AGE OF ONSET: RESULTS FROM THE JUVENILE SCLERODERMA INCEPTION COHORT. WWW.JUVENILE-SCLERODERMA.COM / *I. Foeldvari** - *J. Klotsche* - *O. Kasapcopur* - *A. Adrovic* - *V. Stanevicha* - *T. Terreri* - *E. Alexeeva* - *M. Katsikas* - *V. Smith* - *J. Anton* - *R. Cimaz* - *M. Kostik* - *T. Lehman* - *W.-A. Sifuentes-Giraldo* - *F. Sztajn bok* - *T. Avcin* - *M. Janarthanan* - *M. Moll* - *D. Nemcova* - *M. J. Santos* - *C. Battagliotti* - *J. Brunner* - *D. Eleftheriou* - *L. Harel* - *T. Kallinich* - *K. Minden* - *S. Nielsen* - *K. Torok* - *Y. Uziel* - *A. Stevens* - *C. Pilkington* - *N. Helmus*
- P301** ASSESSING THE PREVALENCE OF JUVENILE SYSTEMIC SCLEROSIS IN CHILDHOOD USING ADMINISTRATIVE CLAIMS DATA FROM THE UNITED STATES / *I. Foeldvari** - *T. Beukelman* - *F. Xie*
- P302** PROPOSAL FOR A JUVENILE SYSTEMIC SCLEROSIS RESPONSE INDEX(JSSCRI): RESULT OF THE CONSENSUS MEETING IN HAMBURG. GERMANY 11TH OF DECEMBER 2016. / *I. Foeldvari** - *D. Furst* - *J. Anton* - *E. Baildem* - *M. Blakley* - *T. Constantin* - *P. Costa Reis* - *M. Curran* - *M. Cutolo* - *C. Denton* - *K. Fligelstone* - *B. Hinrichs* - *F. Ingegnoli* - *A. Kienast* - *D. Němcova* - *C. Pain* - *C. Pilkington* - *V. Smith* - *D. Khanna*
- P303** CLINICAL EVALUATION OF 34 CHILDREN WITH SYSTEMIC SCLEROSIS:A MULTICENTER STUDY / *R. Sinaei** - *Y. Aghighi* - *R. Shiari* - *S. R. Raeeskarami* - *F. F. Mehrgan* - *V. Ziaee* - *K. Rahmani* - *V. Javadi Parvaneh* - *M. Hassas Yegane* - *A. Ahmadzadeh* - *M. R. Fathi* - *S. Pezashki*
- P304** A BOY WITH THE AGING HANDS AND DYSTROPHIC FINGERNAILS / *M. Yiallourides** - *R. Noakes*

Spondyloarthritis (SpA) and enthesitis related arthritis (ERA)

- P305** IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME ASSOCIATED WITH JUVENILE ENTHESIS-RELATED ARTHRITIS UNDER TREATMENT OF ADALIMUMAB AND TUBERCULOSIS / *T. Miyamae** - *Y. Tani* - *T. Hara* - *A. Hanaya* - *H. Yamanaka*

Systemic juvenile idiopathic arthritis

- P306** CLINICAL AND LABORATORY ASSESSMENT OF A SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS COHORT: A RETROSPECTIVE STUDY / *A. L. Boteanu** - *M. Llop Vilaltella* - *M. A. Blazquez Cañamero* - *S. Garrote Corral* - *C. Bouroncle Alaluna* - *M. Gamir Gamir*
- P307** THE DISEASE BURDEN OF SJIA FOR PATIENTS AND CAREGIVERS: AN INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE SURVEY AND RETROSPECTIVE CHART REVIEW / *G. Horneff** - *S. Shenoj* - *M. Cidon* - *A. V. Ramanan* - *Y. Kimura* - *P. Quartier* - *I. Foeldvari* - *A. Zeff* - *K. G. Lomax* - *J. Gregson* - *T. Abma* - *S. Campbell* - *J. Weiss* - *N. Marinsek* - *D. Patel* - *N. Wulffraat*
- P308** IDENTIFICATION OF BEST CUT-OFF POINTS AND CLINICAL SIGNS FOR DISCRIMINATION OF ACUTE LYPHOBLASTIC LEUKEMIA AND SYSTEMIC ONSET OF JUVENILE IDIOPATHIC ARTHRITIS DEPENDING ON PRESENCE OF MACROPHAGE ACTIVATION SYNDROME. / *M. M. Kostik** - *E. Isupova* - *I. Chikova* - *T. Panova* - *O. Kopchak* - *M. Dubko* - *V. Masalova* - *L. Snegireva* - *T. Komishina* - *O. Kalashnikova* - *V. Chasnyk*
- P309** RECURRENT MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH HETEROZYGOUS UNC 13D GENE MUTATION IN A CHILD WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / *B. Makay** - *S. Gözmen* - *Y. Ay* - *T. Hilkey Karapinar* - *Y. Oymak* - *N. Gülez* - *C. Vergin*
- P310** WITHDRAWAL OF CANAKINUMAB IN PATIENTS WITH SJIA, MAYBE WE "CAN"! A REAL LIFE SINGLE CENTER EXPERIENCE / *D. Maritsi** - *S. Papailiou* - *M. Papatesta* - *M. Tsolia* - *O. Vougiouka*

- P311** GENERALIZED LYMPHADENOPATHY IN A CHILD WITH SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ANAKINRA / *E. Marrani* - M. C. Caparello - T. Giani - G. Simonini - R. Cimaz*
- P312** NASAL SEPTAL PERFORATION IN A CHILD WITH RECURRENT MACROPHAGE ACTIVATION SYNDROME SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS / *V. Selmanovic* - A. Omercahic-Dizdarevic - A. Cengic - D. Pokrajac - S. Hasanbegovic - S. Zubcevic - D. Anic - M. Debeljak*

Systemic lupus erythematosus and antiphospholipid syndrome

- P313** CLUSTER ANALYSIS AND CLINICAL ASSOCIATIONS OF AUTO ANTIBODIES IN PEDIATRIC SLE - A SINGLE CENTER COHORT STUDY / *S. Kumar* - S. Prasad - V. Jeyaseelan*
- P314** CLINICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BOYS ACCORDING TO 5-YEARS EXPERIENCE IN SINGLE CENTER / *A. Latypova* - M. Kaleda - S. Rodionovskaya - I. Nikishina*
- P315** CLINICAL FEATURES ASSOCIATED WITH HISTOLOGICAL PATTERN IN CHILDHOOD LUPUS NEPHRITIS / *V. Litta-Modignani* - F. Baldo - C. V. Agostoni - M. Giani - G. Montini - G. Filocamo*
- P316** EVALUATION OF HMGB1 AND ITS VARIOUS POST-TRANSLATIONAL FORMS IN JSLE / *A. Midgley* - D. Antoine - M. Beresford*
- P317** AQUAPORIN-4 ANTIBODIES IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS / *E. Moraitis* - M. Al-Obaidi - K. Mankad - Y. Hacohen - C. Hemingway - D. Eleftheriou*
- P318** COMPARISON OF THE ACR AND SLICC CLASSIFICATION CRITERIA IN BORDERLINE (AGED 16-18 YEARS) JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / *C. Pamfil* - L. Damian - M. Deac - I. Felea - S.-P. Simon - L. Muntean - I. Szabo - E. Candrea - G. Gusetu - S. Rednic*
- P319** CAPTURING THE INITIAL PROFILE OF THE PEDIATRIC SLE IN GREEK PATIENTS / *P. Pratsidou-Gertsis* - M. Trachana - O. Vougiouka - E. Atsali - F. Kanakoudi-Tsakalidou*
- P320** EPIDEMIOLOGY OF LUPUS IN ESTONIAN CHILDREN IN 2012-2016 / *C. Pruunsild* - S. Tarraste - J. Ilisson*
- P321** SCREENING FABRY DISEASE IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS / *E. Kiykim - S. Sahin* - T. Zubarioglu - K. Barut - A. Adrovic - M. S. Cansever - C. Aktuglu-Zeybek - O. Kasapcopur*
- P322** ARE PREMATUREITY AND ENVIRONMENTAL FACTORS DETERMINANTS FOR DEVELOPING CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOUSUS? / *P. G. Conde - L. C. Farhat - A. L. Braga - A. E. Sallum* - S. C. Farhat - C. A. Silva*
- P323** CAPILLAROSCOPY FINDINGS IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS, A DUTCH EXPERIENCE OF 22 CHILDREN AND ADOLESCENTS / *D. Schonenberg-Meinema* - M. vd Berg - A. Nassar-Sheikh-Rashid - G. de Bree - L. Hak - M. van Onna - K. Melsens - M. Cutolo - T. Kuijpers - V. Smith*
- P324** FICOLIN H IN PEDIATRIC SLE COHORT FROM NORTH INDIA / *A. K. BN - M. Sharma* - A. Rawat - A. Gupta - S. Singh*
- P325** PAEDIATRIC LUPUS NEPHRITIS - A SINGLE-CENTRE EXPERIENCE OF OVER 10 YEARS / *C. Sirbe* - I. E. Szabo - B. Bulata - M. Spirchez - D. Delean - S. Rednic*
- P326** LONG-TERM QUANTITATIVE ASSESSMENT OF THE PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS GRAVITY.FACTORS THAT AFFECT THE DISEASE OUTCOME / *M. Trachana* - P. Pratsidou-Gertsis - F. Kanakoudi-Tsakalidou - F. Papachristou*
- P327** CHYLOUS ASCITES AND PODOCYTOPATHY AS PRESENTING FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A YOUNG CHILD / *P. Vignesh* - R. K. Pilia - S. Guleria - D. Suri - A. Gupta - A. Rawat - R. Nada - S. Singh*

Treatment

- P328** PERSISTENCE WITH FIRST BIOLOGICAL AGENT AND REASONS FOR DISCONTINUATION IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE PORTUGUESE REGISTER, REUMA.PT. / *A. F. Mourão* - M. Eusébio - J. Melo-Gomes - F. Oliveira-Ramos - F. Martins - P. Estanqueiro - M. Salgado - M. Guedes - M. Conde - S. Carvalho - J. Costa - I. Brito - C. Duarte - C. Furtado - A. Rodrigues - G. Sequeira - R. Campanilho-Marques - J. Branco - M. J. Santos - J. Eurico Fonseca - H. Canhão*
- P329** THE INFLUENCE OF BIOLOGICAL THERAPY ON THE PHYSICAL DEVELOPMENT OF CHILDREN WITH JIA / *O. A. Oshlyanska* - L. I. Omelchenko - J. V. Biliavska - V. M. Kovalenko*

- P330** A FIVE YEAR U.K. TERTIARY PAEDIATRIC RHEUMATOLOGY CENTRE EXPERIENCE FOR THE USE OF RITUXIMAB / *N. K. Rafiq* - M. Wood - V. Leone*
- P331** EVALUATION OF LONG TERM SAFETY AND INDICATIONS OF BIOLOGIC AGENTS IN JUVENILE RHEUMATIC DISEASES: A SINGLE CENTER EXPERIENCE IN TURKEY / *S. Sahin* - S. Bektas - E. Belhan - D. Hopurcuoglu - A. Adrovic - K. Barut - O. Kasapcopur*
- P332** THE EXPERIENCE OF ORAL AND PARENTERAL METHOTREXATE THERAPY IN THE JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / *B. Sozeri* - A. Adrovic - N. Aktay Ayaz - S. G. Ercan - H. Ankan - A. Kaplan - K. Barut - M. Cakan - S. Sahin - O. Kasapcopur*
- P333** METHOTREXATE IN JIA: SUSTAINABILITY OF EARLY REMISSION ACHIEVED WITH SUBCUTANEOUS ADMINISTRATION / *S. Fingerhutova - K. Kobrova - D. Cebecauerova - R. Srp* - J. Franova - D. Nemcova - M. Uher - P. Dolezalova*
- P334** A NOVEL TRANSDERMAL HYDROGEL-FORMING MICRONEEDLES PATCH A PROMISING SYSTEM TO DELIVER METHOTREXATE FOR JIA PATIENTS / *I. A. Tekko - R. F. Donnelly - H. McCarthy - J. McElnay - M. Rooney**

Uveitis

- P335** PREVALENCE AND CHARACTERISTICS OF UVEITIS IN A COHORT OF PORTUGUESE JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / *F. Aguiar - R. Ferreira* - M. Rodrigues - L. Figueira - L. Torrão - I. Brito*
- P336** CYCLOPHOSPHAMIDE, A SIGHT FOR SORE EYES: A CASE OF REFRACTORY UVEITIS SUCCESSFULLY TREATED WITH CYCLOPHOSPHAMIDE / *S. Rasul* - A. Chieng - J. Ashworth - N. Jones on behalf of Royal Manchester Children's Hospital.*
- P337** EFFICACY OF INFLIXIMAB IN TREATMENT OF RESISTANT UVEITIS IN PEDIATRIC RHEUMATOLOGIC DISEASES / *S. Salehi* - R. Shiari - M. Soheilian*
- P338** A LONG-TERM GREEK STUDY ASSESSING THE SAFETY AND EFFICACY OF ADALIMUMAB IN PEDIATRIC PATIENTS WITH REFRACTORY NON-INFECTIOUS UVEITIS / *M. Trachana* - P. Pratsidou-Gertsis - E. Koulali - N. Kozeis - P. Tranos - A. Doudou - S. Androudi*

Vasculitides

- P339** HIGH RISK OF CARDIAC CORONARY ANEURYSM IN YOUNG CHILDREN WITH INCOMPLETE KAWASAKI DISEASE / *M. Mossberg - A. J. Mohammad - M. Segelmark - R. Kahn**
- P340** JUVENILE POLYARTERITIS NODOSA PRESENTING AS REFRACTORY KAWASAKI DISEASE: A DIAGNOSTIC CHALLENGE IN YOUNG INFANTS / *P. Khaosut* - P. Chatchatee - H. Chantaphakul*
- P341** HYPOMORPHIC RAG1 DEFECT IN A CHILD PRESENTED WITH PULMONARY HEMORRHAGE AND DIGITAL NECROSIS / *H. E. Sönmez* - E. D. Batu - E. Z. Taşkıran - D. Ç. A. Ç. Ayvaz - C. Koşukcu - S. Esenboğa - R. Topaloğlu - D. Orhan - Y. Bilginer - M. Alikasıfoğlu - S. Özen - I. Tezcan*
- P342** TO PREDICT THE RISK OF RECURRENCE OF HENOCH-SHÖNLEIN PURPURA IN CHILDREN / *G. Yıldırım Usta - E. Usta - I. Islek - B. Sozeri**
- P343** COMPARISON OF PATIENTS WITH IGA VASCULITIS IN MEDITERRANEAN AND CONTINENTAL PART OF CROATIA / *S. Srsen* - M. Frkovic - V. Metlicic - L. Stricevic - M. Pecnjak - M. Held - M. Jelusic*
- P344** CMV INFECTION AS A COMPLICATION OF GPA IMMUNOSUPPRESSIVE THERAPY IN THE TEENAGE PATIENT: DIAGNOSTIC AND THERAPEUTIC CHALLENGES / *M. B. Tomaszek* - A. Rybkowska - A. Sobiesiak - V. Opoka-Winiarska*
- P345** PEDIATRIC-ONSET BEHÇET'S DISEASE: AN EXPERIENCE FROM A TERTIARY-CARE CENTRE IN NORTH INDIA / *P. Vignesh* - R. K. Pilonia - A. Sharma - D. Suri - A. Gupta - B. Saikia - R. W. Minz - A. Rawat - S. Singh*
- P346** POLYARTERITIS NODOSA IN CHILDREN, CLINICAL CHARACTERISTICS AND COURSE, IN A THIRD LEVEL HOSPITAL IN MEXICO CITY. / *A. V. Villarreal - T. Diaz Prieto* - Y. Ramirez Loyola - E. Faugier Fuentes - M. D. R. Maldonado Velazquez*
- P347** SIMULTANEOUS OCCURRENCE OF KAWASAKI DISEASE AND SALMONELLA INFECTION WITH A POSITIVE DENGUE SEROLOGY / *V. Viswanathan* - P. Andankar - N. Gupta - I. Singh - M. Rajguru - S. Laxmivenkateshaiah*
- P348** UNUSUAL INFECTIONS AND KAWASAKI DISEASE: CAUSE, CORRELATION, OR COINCIDENCE? / *V. Viswanathan* - I. Singh - A. Deshmukh - S. Sane - L. Srinivas*



SUNDAY 17 SEPTEMBER

SCIENTIFIC SESSIONS

ORAL PRESENTATIONS

08:30 - 10:00 **Oral presentations** Banquet Hall

Chairs: Yosef Uziel (Israel), Athimalaipet Ramanan (United Kingdom)

08:30 **O25** - Single cell RNA-sequencing of bone marrow macrophages identifies a distinct subpopulation in systemic juvenile idiopathic arthritis (JIA) with features of interferon response, endocytic vesicles and phagocytosis

Grant Schulert (USA)

08:40 **O26** - Adjudication of infections from the pharmacovigilance in juvenile idiopathic arthritis patients (pharmachild) treated with biologic agents and/or methotrexate with a focus on opportunistic infections

Gabriella Giancane (Italy)

08:50 **O27** - Use of whole-body magnetic resonance to identify potential diagnostic clues in children with fever of unknown origin (FUO)

Sara Signa (Italy)

09:00 **O28** - Usefulness of magnetic resonance imaging in early assessment of low back pain with possible inflammatory cause in children

Lovro Lamot (Croatia)

09:10 **O29** - Efficacy and safety of Canakinumab in patients with HIDS/MKD: results from the pivotal phase 3 cluster trial

Joost Frenkel (The Netherlands)

09:20 **O30** - Efficacy, safety, pharmacokinetics and pharmacodynamics of canakinumab in patients with TRAPS: results from the pivotal phase 3 cluster trial

Marco Gattorno (Italy)

09:30 **O31** - Evidence based recommendations for corticosteroid tapering/discontinuation in new onset juvenile dermatomyositis patients from the PRINTO trial

Gabriella Giancane (Italy)

09:40 **O32** - Evaluation of varicella zoster immune status in children with rheumatic diseases treated with biologic agents

Elena Moraitis (United Kingdom)

09:50 **O33** - Prolonged reduced aerobic fitness in adolescents and young adults with juvenile idiopathic arthritis

10:00-10:30 **Coffee break**

PReS SESSIONS

10:30 - 12:10 ● **Epidemiology and challenges in management of childhood-onset systemic lupus erythematosus (SLE) around the world** Banquet Hall

Chairs: Sujata Sawhney (India), Claudia Saad-Magalhães (Brazil)

10:30 Childhood-onset systemic lupus erythematosus (SLE) in Europe

Angelo Ravelli (Italy)

10:55 Childhood-onset systemic lupus erythematosus (SLE) in South America

Clovis Silva (Brazil)

11:20 Childhood-onset systemic lupus erythematosus (SLE) in Asia

Amita Aggarwal (India)

11:45 Childhood-onset systemic lupus erythematosus (SLE) in Africa

Christian Scott (South Africa)

10:30 - 11:45 ● **Pharmacotherapy of juvenile idiopathic arthritis (JIA)** Skalkotas Hall

Chairs: Claas Hinze (Germany), Miroslav Harjaček (Croatia)

10:30 Measurement of biologic drug levels and anti-drug antibodies – is it clinically meaningful?
Gertjan Wolbink (The Netherlands)

11:00 JAK inhibitors for treatment of juvenile idiopathic arthritis (JIA)
Daniel Lovell (USA)

11:30 **O34** Contextualizing guidelines for the management of juvenile idiopathic arthritis in developing countries: a needs assessment
Mercedes Olivia Chan (Canada)

12:10-12:30 **Break**

12:30 - 14:00 ● **Thieves market** Banquet Hall

Chairs: Joost Frenkel (The Netherlands), Raju Khubchandani (India)

Presenters: Roberta Caorsi (Italy), Francesca Minoia (Italy), Mojca Zajc Avramovic (Slovenia), Prajakta Joshi Ranade (India), Pallavi Pimpale (India), Katerina Theodoropoulou (Switzerland), Maria Tsinti (Greece)

14:00 - 14:30 **Closing**

Berent Prakken (The Netherlands), Elena Tsitsami (Greece)

ENCA PROGRAMME

FRIDAY 15 SEPTEMBER

OTHER INFLAMMATORY DISEASES, LATEST RESEARCH AND PRES

MC2 Room

09:00 - 10:30 Other inflammatory diseases, latest research and PReS

- 09:00 Opening reports, introduction of participants, winner of the contest "Fun with JIA"
Wendy Costello (Ireland), Yona Egert (Israel)
- 09:45 Other inflammatory diseases – KAISZ Netherlands
Saskya Angevare (Netherlands)
- 10:10 Other inflammatory diseases – Lupus UK
Kevin Weston (United Kingdom)

10:30-11:00 Coffee break

11:00 - 12:00 Introduction of ENCA members' associations

Greece
Italy
Ireland

12:00 - 12:30 Focus groups

What is the biggest problem in your country?
What is the biggest advantage in your country?

12:30 - 12:40 Photoshooting

12:30-14:00 Lunch break

14:00 - 15:00 New developments and new strategies: optimising treatment in juvenile idiopathic arthritis (JIA)

Lucy Wedderburn (United Kingdom)

15:00 - 17:00 PReS/ENCA joint session:

Skalkotas Hall

Parent and child perspectives on physician communication in pediatric rheumatology

Chairs: Nico Wulffraat (The Netherlands), Pavla Dolezalova (Czech Republic)

- 15:00 Introduction of European Network for Children with Arthritis (ENCA)
Wendy Costello (Ireland)
- 15:15 What is really bothering my patient and his/her parents? - Patient perspective
Simon Stones (United Kingdom) & Sarah Dalton (United Kingdom)
- 15:40 What is really bothering my patient and his/her parents? - Parent perspective
Mirjam Kepic (Slovenia) & Glenda Dalton (United Kingdom)
- 16:10 What is really bothering my patient and his/her parents? - Health professional perspective
Jan Jaap van der Net (The Netherlands)
- 16:30 Insight and recommendations resulting from analysis of parent survey in SHARE project
Bas Vastert (The Netherlands) & Tsipi Egert (Israel)

ENCA PROGRAMME

SATURDAY 16 SEPTEMBER

PAIN MANAGEMENT, SELF-MANAGEMENT, TEENS AND US

MC2 Room

09:00 - 09:10 Welcome

*Wendy Costello (Ireland), Yona Egert (Israel), Anita van de Louw (The Netherlands)
Anton Gruss (France) and Mirjam Kepic (Slovenia)*

09:10 - 09:30 Adolescent issues

09:10 Patient story

Simon Stones (United Kingdom), Manca Kepic (Slovenia)

09:30 - 10:00 Introduction of associations

Belgium
Slovenia

10:00 - 10:30 Focus groups

10:00 Results of survey, questions and debate

Anita van de Louw (The Netherlands)

10:30-11:00 Coffee break

11:00 - 12:00 Teenage, drugs, alcohol, sex

Catherine Wright (United Kingdom), Margarita Tsitsi (Greece)

12:00 - 12:20 Introduction of association

Sweden

12:20 - 12:40 Debate

12:20 Participating at ENCA

Wendy Costello (Ireland), Anita van de Louw (The Netherlands)

12:40-14:00 Lunch break

14:00 - 15:00 Self-management and pain management

14:00 Voting for ENCA new board members

14:10 Coping with pain from a biopsychological perspective

Lizanne Bentvelsen (The Netherlands)

14:25 Back and forth: coping with juvenile idiopathic arthritis (JIA) in school

Jeannette Cappon (The Netherlands)

14:40 Bordergame: a communication board game to play with family

Yvonne Heijligers (The Netherlands)

15:00 - 15:30 Doctor vs. Rheumatologist vs. Pediatric rheumatologist and vaccination

Nico Wulffraat (The Netherlands)

15:30 - 16:00 Closing

Meeting next year, main topics for next year, suggestions, new contest and goodbye

Wendy Costello (Ireland)

FRIDAY 15 SEPTEMBER

SATELLITE SYMPOSIA PROGRAMME

13:00 - 14:00 **Abbvie**

Banquet Hall

Defining treatment strategies and comorbidities in JIA:
Is there evidence for clinical consistency to optimize
clinical practice?

abbvie

Chair: Angelo Ravelli (Italy)

13:00 Welcome and introduction

Angelo Ravelli (Italy)

13:05 New paradigms in treat-to-target for JIA

Angelo Ravelli (Italy)

13:20 Seeking clinical consistency in the treatment of pediatric uveitis: What do the data tell us?

Athimalaipet V. Ramanan (United Kingdom)

13:35 Translating the data into real-world clinical practice

Eric Fortin (Canada)

13:50 Panel discussion

All

13:00 - 14:00 **Pfizer**

Skalkotas Hall

Treatment strategies in JIA: Delivering tomorrow

Chair: Nicolino Ruperto (Italy)

Pfizer

13:00 Chairman's welcome. Treatment of JIA today: PReSent, but correct?

Nicolino Ruperto (Italy)

13:10 What role can biosimilars play for our patients?

Rieke Alten (Germany)

13:30 Taking JIA into the future: novel therapies and new horizons

Hermine Brunner (USA)

13:50 Interactive audience discussion

All

14:00 Summary and close

Nicolino Ruperto (Italy)

13:00 - 14:00 **Biomarin & Sanofi Genzyme**

MC 3 Room

When is JIA not JIA? A case-led discussion of
its mimics

Chair: Helen Foster (United Kingdom)

B:OMARIN[®]

BioMarin Europe Ltd.

13:00 MPS in the rheumatology setting: an introduction

Helen Foster (United Kingdom)

13:10 Red-flag symptoms for MPS: when is JIA not JIA?

Rolando Cimaz (Italy)

SANOFI GENZYME

13:30 Improving clinical outcomes of MPS patients: treatment and management strategies

Julian Raiman (United Kingdom)

13:50 Questions and summing up


SATURDAY 16 SEPTEMBER

SATELLITE SYMPOSIA PROGRAMME

13:00 - 14:00 **Novartis** Banquet Hall

Novel approaches: Targeting IL-1 β
The molecular signature of autoinflammatory disease

Chair: Jasmin Kümmerle-Deschner (Germany)




- 13:00 Living with systemic juvenile idiopathic arthritis and periodic fever syndromes: Perspectives from patients and their caregivers
Nico Wulffraat (The Netherlands)
- 13:15 New management strategies for Still's disease
Dirk Föll (Germany) and Eugen Feist (Germany)
- 13:30 IL-1 Inhibition - Opportunities and challenges in the treatment of periodic fever syndromes
Jasmin Kümmerle-Deschner (Germany)
- 13:45 Panel Discussion/Q&A
Jasmin Kümmerle-Deschner (Germany)

13:00 - 14:00 **ENZYVANT** Skalkotas Hall

Therapy Refractory JIA? Think Farber Disease

Chair: Seza Ozen (Turkey), Boris Hügler (Germany)



- 13:00 Greeting and introduction
Seza Ozen (Turkey)
- 13:05 Sphingolipids in inflammation and Farber disease
Edward H. Schuchman (USA)
- 13:20 JIA or Farber disease? Clinical spectrum and differential diagnosis
Boris Hügler (Germany)
- 13:35 Cases from the Pediatric Rheumatology Clinic:
Moderators: Seza Ozen (Turkey), Boris Hügler (Germany)
1. Severe phenotype - Onset in infancy
Bo Magnusson (Sweden)
 2. Moderate phenotype - Rapid progression
Balahan Makay (Turkey)
 3. Moderate phenotype - Slower progression
Boris Hügler (Germany)
- 13:55 Summary and conclusion
Boris Hügler (Germany)

SPONSORS AND EXHIBITORS PROFILE



ABBVIE

Piazza P1 to P4

Address: 1 North Waukegan Road, North Chicago, IL 60064, United States

Email: www.abbvie.com/contact-webapp/contact.html

Website: www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs approximately 29,000 people worldwide and markets medicines in more than 170 countries.

For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow www.twitter.com/abbvie or @abbvie on "Twitter" or view careers on our www.facebook.com/abbviecareers "Facebook" or www.linkedin.com/company/abbvie "LinkedIn page".



ALEXION PHARMA GMBH

BOOTH 2

Address: Giesshübelstrasse 30, CH-8045 Zürich, Switzerland

Website: www.alexionpharma.eu

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders.

Alexion's global metabolic franchise includes two enzyme replacement therapies – Strensiq® for hypophosphatasia and Kanuma® for lysosomal acid lipase deficiency. Alexion also developed Soliris®, the first and only approved complement inhibitor to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome. Alexion is advancing its rare disease pipeline, with highly innovative product candidates in multiple therapeutic areas.



BIOMARIN

BOOTH 6

BioMarin Europe Ltd.

Address: BioMarin Europe Ltd, 10 Bloomsbury Way, London WC1A 2SL, United Kingdom

BioMarin, we focus on developing first-in-class or best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast in its original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations, made up mostly of children, suffer from diseases so rare, that they can affect as few as 1,000 people worldwide. These conditions are often difficult to diagnose, progressively debilitating and have few, if any, treatment options.



PEDIATRIC
RHEUMATOLOGY

BMC

BOOTH 3

Address: 236 Gray's Inn Road, London, WC1X 8HB, United Kingdom

Email: info@biomedcentral.com

Website: www.biomedcentral.com

A pioneer of open access publishing, BMC has an evolving portfolio of high quality peer-reviewed journals including broad interest titles such as BMC Biology and BMC Medicine, specialist journals such as Malaria Journal and Microbiome, and the BMC series.

At BMC, research is always in progress. We are committed to continual innovation to better support the needs of our communities, ensuring the integrity of the research we publish, and championing the benefits of open research. BMC is part of Springer Nature, giving us greater opportunities to help authors connect and advance discoveries across the world.



ENZYVANT

ENZYVANT

BOOTH 5

Enzyvant is a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, including Farber disease (acid ceramidase deficiency), a rare lysosomal storage disease often misdiagnosed as juvenile idiopathic arthritis (JIA). Patients with Farber disease present with joint contractures or arthritis, subcutaneous nodules, and a hoarse or weak voice. Enzyvant is currently enrolling patients in a natural history study and is preparing a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease.



A Member of the Roche Group

GENENTECH

SPONSOR

Address: 1 DNA Way, 94080 San Francisco, CA, USA

Website: www.gene.com

Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit www.gene.com.



NOVARTIS

NOVARTIS

SPONSOR

Address: Novartis Campus, CH 4056, Basel, Switzerland

Email: serge.smeets@novartis.com / nadine.chapman-rothe@novartis.com

Website: www.novartis.com

Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The name Novartis is derived from the Latin novae arts, which means "new skills", and reflects our commitment. Novartis has a diverse healthcare portfolio, including innovative pharmaceuticals, eye care products and generics.

Our mission is to discover new ways to improve and extend people's lives. Our vision is to be a trusted leader in changing the practice of medicine. Our strategy is to use science-based innovation to deliver better patient outcomes. We want to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. Our focus is on patients — they are the reason we do what we do.



PFIZER

SPONSOR

Address: 235 E. 42nd Street , 10017, New York, NY, USA
Website: www.Pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.



PRINTO

BOOTH 4

Address: IRCCS Istituto G. Gaslini, Pediatria II, Via Gaslini 5, 16147 Genova, ITALY
Website: www.printo.it

The Paediatric Rheumatology International Trials Organisation (PRINTO) is a not for profit, non governmental, international research network founded by Alberto Martini and Nicolino Ruperto in 1996, and initially included 14 European countries (now more than 60 and more than 550 centres worldwide), with the goal to foster, facilitate and co-ordinate the development, conduct, analysis, and reporting of multi-centres, international clinical trials and/or outcome standardisation studies in children with paediatric rheumatic diseases (PRD).



ROCHE

SPONSOR

Address: Grenzacherstrasse 183, 4070 Basel, Switzerland
Email: www.roche.com/contact.htm
Website: www.roche.com

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management..



SANOFI GENZYME

SPONSOR

Address: Gooimeer 10, 1411 DD Naarden, The Netherlands
Website: www.sanofigenzyme.com

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, oncology, and immunology.

We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

SKALKOTAS FOYER

LEVEL -1




LIST OF EXHIBITORS

	P1	P2	P3	P4
ABBVIE				
ALEXION				
BIOMARIN				
BMC				
ENZYVANT				
PRINTO				
SOBI				

BANQUET FOYER

LEVEL -2



**BANQUET
FOYER**
Level -2



LOOK BEYOND THE OBVIOUS

LOW ALKALINE PHOSPHATASE ACTIVITY causes **HYPOPHOSPHATASIA (HPP)**, a progressive, debilitating and potentially life-threatening rare disease that affects patients of all ages.¹⁻³

**LOOK FOR LOW ALKALINE
PHOSPHATASE, HAVE YOU SEEN IT?**

www.gobeyondtheobvious.eu

MedInfo.EMEA@alexion.com

ALEXION[®]

1. Whyte MP. *Ann N Y Acad Sci.* 2010;1192:190-200. / 2. Mornet E, Nunes ME, eds. *GeneReviews*. Seattle, WA: University of Washington, Seattle; 1993. <https://www.ncbi.nlm.nih.gov/books/NBK1150/>. / 3. Rockman-Greenberg C. *Pediatr Endocrinol Rev.* 2013;10(suppl 2):380-388. EMEA/UNB-HPP/17/0022c

CONTRIBUTING SPONSORS

PReS would like to thank the following sponsors for their contribution.

PLATINUM

abbvie



GOLD

B:OMARIN®

SPONSORS

ALEXION



SANOFI GENZYME



PEDIATRIC
RHEUMATOLOGY



sobi
Pioneer in Rare Diseases

Genentech
A Member of the Roche Group

Treatment strategies in JIA: Delivering tomorrow

Friday 15 September, 13.00 – 14.00

Room: Nikos Skalkotas Hall

Chairman: Dr Nicolino Ruperto

Speaker: Dr Rieke Alten

Speaker: Dr Hermine Brunner

